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ABSTRACT 
INTRODUCTION: Dietary factors in the form of citrus juices (e.g orange, grapefruits, 
cranberry, lemonade and lime) appear to affect the ability of urine to inhibit calcium 
oxalate crystallization. In South Africa, previous studies have demonstrated that black 
and white individuals respond differently to lithogenic and antilithogenic dietary 
supplements. 
OBJECTIVES: The current project was undertaken to study the inhibitory activity of 
lime in artificial urine and in the real urine of South African black and white subjects and 
also to assess the effects on urinary risk factors in these subjects after its ingestion. 
SUBJECTS AND METHODS: Experiments commenced with the preparation of 
artificial urine (AU) in which the effects oflime solutions (0.125-1.00 mglml) were tested 
by carrying out various crystallization experiments. These included the determination of 
the calcium oxalate (CaOx) metastable limit (MSL); particle volume-size distribution 
(PSD), nucleation, aggregation and growth assays. Crystal deposition was studied using 
scanning electron microscopy (SEM). 
In vitro experiments were then conducted in 24 hour urine samples from healthy South 
African black (n = 5) and white males (n = 5). The above-mentioned crystallization 
experiments were repeated in these urines. In addition, free Ca2+ values and the Bonn risk 
index (BRI) of CaOx crystallization were determined. 
Thereafter, a trial study in which 5 black and 4 white subjects ingested solutions of lime 
powder for 7 days was conducted. 24 hour urine samples were collected by subjects 
before and after the ingestion of lime. Urines were analysed for pH, sodium, potassium, 
calcium, oxalate, citrate, uric aci~ chloride, magnesium, phosphate, and creatinine. Urine 
composition values were used as input data for the calculation of relative supersaturation 
(RS) values for calcium oxalate monohydrate (COM), calcium oxalate dihydrate (COD), 
brushite and uric acid using the computer programme EQUIL and Tiselius Risk Index 
{TRI) was also determined. The above-mentioned CaOx crystallization experiments were 
also performed. Urine compositions, crysta11ization data and physicochemical risk indices 
were analyzed statistically using analysis of variance (ANOVA). 
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RESULTS: None of the lime solutions did affect the CaOx MSL of the AU or the real 
urine (in vitro). However CaOx crystal nucleation was promoted while CaOx crystal 
growth and aggregation were inhibited. In the trial study, after ingestion of lime solutions, 
significant increases in urinary magnesium (1.80 vs 2.75 mmol/24h, p = 0.0001) and 
phosphate (20.9 vs 24.6 mmol/24h, p = 0.023) were observed in black subjects. On the 
other hand, in white subjects, a significant decrease in urinary oxalate (0.3 I 3 vs 0.205 
mmol/24h, p = 0.023) and TRI (304 vs 187, p = 0.0102) were noted. However, lime did 
not increase citrate levels to a significant degree in either group. 
CONCLUSIONS: The results presented in this dissertation have shown that lime may be 
regarded as a potential therapeutic agent for reducing the risk of CaOx kidney stones in 
the white group based on the trial study. The results also provide further evidence in 
support of the hypothesis that there is a difference between the black and white 
populations with respect to their handling of lithogenic and antilithogenic dietary 
challenges. However, rigorous controlled trials in healthy subjects and in kidney stone 
patients need to be conducted in future studies to explicitly confirm these findings. 
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ABBREVIATIONS AND SYMBOLS 
ANOVA Analysis of variance 
AU Artificial urine 
A1n Aggregation inhibition 
BMI Body mass index 
BU Black urine 
BRI Bonn risk index 
CaOx Calcium oxalate 
CaP Calcium phosphate 
COM Calcium oxalate monohydrate 
COD Calcium oxalate dihydrate 
COT Calcium oxalate trihydrate 
GAGs Glycosaminoglycans 
In Inhibition 
Ia Inhibition growth 
MSL Metastable limit 
Na20x Sodium oxalate 
N1n Nucleation inhibition 
OD Optical density 
p Probabilities 
PSD Particle volume-size distribution 
RE Retinol equivalents 
RS Relative supersaturation 
SE Standard error 
SEM Scanning electron microscopy 
TIIP Tamm-Horsfall protein 
UPTFI Urinary prothrombin fragment- I 
wu White urine 
Tris Tris (hydroxylmethyl)methylamine 
XRD x-ray powder diffraction 
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Urolithiasis is a medical term for kidney stone disease, the most common chronic kidney 
condition dating back to ancient times. It occurs throughout the world in about 8-20 % of 
the population in western societies (Pak 1998; Ramello et al. 2000; Daudon 2005; Lopez 
and Hoppe 2008). Intriguingly, the incidence of these stones in the South African black 
population is rare compared to that of the South African white population, in which it is 
similar to that which occurs in other western societies (Muskat 1951; Modlin 1967; 
Whalley et al. 1998). This is of great interest as it provides basic scientists with a unique 
opportunity to study the characteristics that cause one group to be stone-free and another 
to be stone-prone. Numerous factors which could be biochemical, physicochemical 
and/or physiological in nature are likely to be involved in this phenomenon. 
1.1 KIDNEY STONES AND THEIR COMPOSITION 
Urinary calculi are hardened mineral deposits that form in the kidneys, ureters or bladder. 
They form when the urine has various ion salts such as calcium and oxalate that nucleate 
to form calcium oxalate (CaOx) which build up in the urinary tract (Robertson et al. 1978 
(a); Coe and Parks 1988; Kumar et al. 2003). 
They start as crystals and develop into a stone over time. They may remain in the kidney 
or become lodged in the tube that carries urine from the kidney to the bladder called the 
ureter, and cause severe pain that begins in the lower back. The lodged stone can block 
the flow of urine, causing pressure to build in the affected ureter and kidney. Small stones 
can spontaneously pass out of the body on their own, even though this can be painful, 
whilst large stones may require surgery or shattering into smaller pieces with sound 
waves in a procedure called extracorporeal shockwave lithotripsy. 
There are several types of urinary stones based on chemical composition, which depend 
on the chemical imbalance in the urine at the time of nucleation and growth. These can be 
divided into 4 main stone types namely calcium (approximately 80 %), uric acid (9 %), 
magnesium ammonium phosphate ("struvite") (10 %) and cystine (1 %) (Finlayson 




The most common cause of calcium stone production is excess calcium in the urine, 
clinically known as hypercalciuria CaOx urolithiasis is a very common disorder and 
these stones may be pure or mixed, usually with calcium phosphate, uric acid or 
ammonium urate (Trinchieri et al. 2005). Calcium oxalate monohydrate (COM) 
(whewellite) and calcium oxalate dihydrate (COD) (weddelite) occur commonly, but 
calcium oxalate trihydrate (COT) is extremely rare (Herring 1962; Streit et al. 1998; 
Grases et al. 1998; Bithelis et al. 2004; El-Shall et al. 2004). The pathogenesis of 
idiopathic CaOx stones formation is multifactorial and these include epidemiological, 
metabolic, physicochemical and dietary factors. All of these will be discussed in the 
following pages. Because of the predominance of these stones; they constitute the focus 
of this dissertation. 
CaP stones 
Calcium phosphate (CaP) stones typically occur in patients with metabolic or hormonal 
disorders such as hyperparathyroidism and renal tubular acidosis (Hess and Jaeger 1993). 
CaP stones exist in numerous forms and amongst them, apatite (calcium hydroxyl 
phosphate) and brushite (calcium hydrogen phosphate) are seen more frequently in 
women (Parks et al. 2004; Worcester and Coe 2008). Brushite stones are very physically 
resistant structures which are difficult to break with shock waves and therefore surgery is 
required to remove this type of stone (Klee et al. 1991 ). On the other hand, apatite stones 
are easily broken by shock wave (Williams Jr et al. 2003; Parks et al. 2004; Evan et al. 
2005). The most important factors for the formation of CaP stones are high urinary pH 
(except for brushite stones which form at a pH below 6.5, Parks et al. 2004), high urinary 
calcium and low urinary citrate (Pak: et al. 2008 (a)). 
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Uric acid stones 
Uric acid is the end product of purine degradation in humans (Coe et al. 2005). It is a 
weak acid with pKa of 5.35 in urine. Approximately 3 % of stone-formers form uric acid 
stones (Nordin and Hodgkinson 1967). These stones are the consequence of 
abnormalities in purine metabolism, urate/uric acid renal handling and/or excess dietary 
protein (William-Larson 1990). Hyperuricosuria, low urinary volume and pH values 
below 5.5 are the well known contributing factors of uric acid stone formation (Shekarriz 
and Stoller 2002). The treatment of uric acid stones includes increased intake of fluid, 
urine alkalinization of pH to values between 6.2 and 6.8 by ingestion of potassium citrate 
or sodium bicarbonate and adoption of a low-purine diet (Ferrari and Bonny 2004). 
Magnesium ammonium phosphate stones 
Magnesium ammonium phosphates (struvite) grow rapidly forming "staghom-calculi". 
The primary cause of these stones is chronic urinary tract infection (Bruyeni et al. 2008; 
G6mez-NWiez et al. 2009). This occurs as a result of micro-organisms such as Proteus, 
Providencia, Klebsiella, Pseudomonas and Enterococci which are hydrolysed by the 
enzyme urease which degrade urea to ammonia and C~, raising the urine pH. These 
conditions favour the formation of struvite (Ramello et al. 2000). 
Cystine stones 
Cystine kidney stones occur due to cystinuria, an inherited disorder of the transport of an 
amino acid called cystine. These stones occur more commonly in children and young 
adults than in adults (Font-Llitj6s et al. 2005). Cystine stones represent only a small 




Aetiological factors for calcium oxalate urolithiasis can be divided into four main 
categories - epidemiological, urinary, combined and physical as shown in Figure 1.1. 


























Figure 1.1 A risk factor model for calcium oxalate stone-formation in the urinary tract (modified from 
Robertson and Peacock 1983) 
Epidemiological Factors 
1.2.1 Geography and climate 
The probability of forming stones varies in different parts of the world. For example in 
Saudi Arabia, the prevalence of kidney stones formation is about 20% (Robertson and 
Hughes 1994 ). In other developed countries, the risk of forming stones is reported as 13 
% in USA, 12% in Canada, 5-9% in Europe and 1-5% in Asia (Ramello et al. 2000). 
People who live in hot or warm climates or those who are exposed to very hot conditions 
are susceptible to kidney stone formation. It is likely that this is caused by dehydration 
with a resultant reduction of urine flow rate and a concomitant increase in the 
concentration of solutes in the urine (Blacklock 1982). 
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Notwithstanding this, the hypothesis that climate has an effect on the risk of kidney stone 
formation is not entirely consistent. This is demonstrated by the observation that in some 
regions of Africa, e.g Nigeria (Esho 1978; Olapade-Olaope et al. 2004), Southern Sudan 
(Kambal et al. 1981), Tanzania (Mkony et al. 1991), and South Africa (amongst the black 
population) (Wise and Kark 1961; Modlin 1967; Whalley et al. 1998), the occurrence of 
stones is rare. 
1.2.2 Occupation 
Many studies have found that there is a higher incidence of stone formation amongst 
certain occupation groups, for instance people in sedentary occupations such as aviation 
pilots and truck drivers (Blacklock 1982; Ferrie and Scott 1984; Borghi et al. 1993; 
Zheng et al. 2002). A possible explanation could be that irregular and insufficient intake 
of fluids leads to increase urinary concentration of stone forming salts. 
1.2.3 Race, Gender and Age 
Generally the incidence of kidney stones has been reported to be relatively higher in 
whites compared to blacks, irrespective of geographical area (Whalley et al. 1998; 
Ramello et al. 2000; Taylor and Curhan 2007). For example, reports have shown that 
urolithiasis in the USA is more prevalent in whites than in blacks (Finlayson and Reid 
1978; Soucie et al. 1994 ), and these reports have been recently supported by Maloney et 
al. (2005) who showed that of 1,141 stone patients from the same region (North Carolina, 
USA) who participated in a metabolic evaluation study, only 9% were non-white. Other 
groups have also been reported to show stone rarity, namely Indians in Mexico, Peru, 
Ecuador and Bolivia (Finlayson 1978), Inuit and Australia's aboriginal population (Scott 
and Mowart 1977). 
In South Africa, about 15 % of the white population are at risk of developing kidney 
stone disease in their life time. On the other hand less than 1 % of the black population 
form stones (Modlin 1967; Meyers et al. 1994; Whalley et al.1998). The latter 




Many studies have shown that urolithiasis is age-dependent, with about 15 % of men and 
5 % of women being afflicted by the time they are 30-60 years old (Ljunhall et al. 1977; 
Hesse et al. 1986; Blacklock 1982; Yoshida and Okada 1990; Iguchi et al. 1999). It is not 
clear why women have a lower incidence of stones, but a few possible explanations have 
been proposed. The first is that elevated uric acid excretion rates occur in a greater 
proportion in males than in females (Coe FL 1978). Second, there is evidence that 
oestrogen protects women against kidney stone (Liao and Richardson 1972; Finlayson 
1974; Heller et al. 2002). Another possible explanation might be that female subjects 
have a higher level of urinary citrate that might protect them from calcium urolithiasis 
(Welshman and McGeown 1975). Conversely, testosterone may increase the risk of stone 
formation by increasing urinary oxalate excretion in males (Lee et al. 1996). 
1.2.4. Genetics 
Urolithiasis is also a genetically-related disease. In a study by Ljunghall et al. (1985), 
55 % of patients disclosed that they had at least one first-degree relative with renal stone 
history. In Italy; Trinchieri et al. (1988) observed that 37 %of cases and Gambaro et al. 
(1996) reported that 38 % of non-current and 50 % of current stone formers have a 
positive family history of nephrolithiasis. In the USA, Curhan et al. (1997 (a)) in a study 
of 3 7 999 men investigated an interaction between family history and dietary factors and 
found that males who had kidney stones are approximately 3 times more likely to have a 
family history of this disease than females. In another study, 36 % of 1223 women 
reported a family history of stones (Curhan et al. 2004). 
1.2.5 Diet 
Many research studies have demonstrated the relationship between dietary intake of 
various nutrients and the excretion of lithogenic and inhibitory substances in the urine 
(Hesse et al. 1993; Curhan 1993, 1996, 1997 (b), 2004; Massey et al. 1993, 2003; 
Rodgers 1997, 1998, Siener and Hesse 2002; Siener et al. 2004; Taylor and Curhan 2004; 




Urinary oxalate is derived from endogenous and exogenous sources. Endogenous oxalate 
production is directly proportional to body weight (Massey 2003). It is synthesised from 
two major sources: approximately 40 % is derived from the end product of ascorbate 
metabolism and approximately 40-50 % is derived from the metabolic reaction involving 
glyoxalic acid (Massey et al. 1993; Robertson 1999). Exogenous oxalate is derived from 
dietary sources occurring in various plant foods (Massey 2003). Approximately half of 
ingested oxalate is used as a substrate by enteric bacteria, and about 25 % is excreted 
unchanged in the faeces (Robertson 1999). Dietary oxalate influences the level of urinary 
oxalate (Kasidas and Rose 1980; Hesse et al. 1993; Holmes and Kennedy 2000; Holmes 
et. al. 2001). As a consequence, CaOx stone patients should be advised to reduce their 
intake of oxalate-rich foods. Spinach, rhubarb, beetroot, nuts, chocolate, legumes, 
parsley, strawberries, concentrated brans and tea contain high levels of oxalate which can 
cause a significant increase in urinary oxalate excretion (Finch et al. 1981 ; Brinkley et al. 
1990; Hesse et al. 1993; Massey et al. 1993, 2003; Holmes et. al. 2001 ), and therefore 
promote the formation of CaOx stones. 
Interestingly, co-ingestion with foods rich in calcium (e.g. dairy products) minimizes the 
rise in urinary oxalate by binding oxalate in the intestinal tract (Curhan et al. 1993; 
Curhan et al. 2004). On the other hand, the rise in urinary oxalate from dietary oxalate is 
more marked when dietary calcium is restricted. (Curhan et al. 1993, 1997 (b), 2004; 
Krieg 2005). 
Dietary calcium 
A high calcium intake is a potential risk factor for stone formation as it raises urinary 
calcium and the saturation of calcium salts (Barilla et al. 1978; Bataille et al. 1983). 
However, a high calcium diet may also lower urinary oxalate by binding oxalate in the 
intestinal tract (Curhan et al. 1993, 1997 (b); Hess et al. 1998; Krieg 2005). 
This will oppose the rise in urinary oxalate and thereby may prevent the formation of 
CaOx crystals in urine (Curhan et al. 1997 (b)). There have been contradicting results 
with regard to whether a high or low calcium intake is suitable for CaOx stone patients. 
For many years, patients were advised to reduce their dietary intake of calcium (Bleich et 




But more recent studies have demonstrated that this is inappropriate and even dangerous 
as the reduction of calcium intake might not only increase the risk of CaOx stone 
formation (by inducing higher absorption and hence higher urinary excretion of oxalate) 
but could also causes a negative calcium balance and further loss of bone tissue (Curhan 
1993; Messa et al. 1997: Hess et al. 1998; Curhan 1999; Lemann 2002). 
Interestingly, Heller et al. (2003) recently reported that a high calcium diet conferred an 
alkali load that produced an increase in urinary pH, potassiUJD, phosphorus and citrate but 
significantly increased relative saturation ratio of CaOx by 24 %. 
It is important to mention that the pathogenic role of dietary calcium on stone formation 
depends on the state of intestinal calcium absorption and on the degree of dietary oxalate 
restriction. Thus, dietary advice for CaOx patients should be focused on maintaining an 
intake between 800 and 1200 mg of calcium per day rather than restricting or exceeding 
the patient's normal intake (Wahl and Hess 2000, Taylor and Curhan 2004). 
Dietary animal protein 
An increase in animal protein consumption has been reported to cause an increase in 
urinary calcium and uric acid excretion (Roberson et al. 1979 (b); Kerstetter 2003; Pak 
2004). 
Studies have demonstrated a relationship between the incidence of stone disease and 
consumption of animal protein (Robertson et al. 1979 (a) and (b); Brockis et al. 1982; 
Hesse et al. 1993; Curhan et al. 1993). In a study by Brockis et al. (1982), dietary habits 
and urine composition of 30 meat-eating subjects were compared with those of vegetarian 
subjects. They found that urinary calcium excretion increased as animal protein intake 
increased. Curhan et al. (1993) showed in a prospective study of dietary calcium and 
other nutrients a 33 % increase in risk of stone disease in men who had no history of 
stone disease who were taking ~ 77 g/day of animal protein as compared to those who 
were taking ~ 50 g/day of animal protein. The proposed mechanism is that high animal 
protein load reduces urinary pH and citrate and increases calcium (Reddy et al. 2002; 
Siener and Hesse 2002). Moreover, it increases urinary uric acid due to its high content of 
purine which is a substrate for urate synthesis (Coe et al. 1976; Krieg 2005). 
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Advice given to kidney stone formers is that they should consume between 0.8 and 1.2 g 
of meat protein per kg body weight per day (Wahl and Hess 2000; Kerstetter et al. 2003). 
Other dietary factors 
Several studies have reported that high carbohydrate intake results in increased urinary 
calcium excretion (Raskin et al. 1978; Wood and Allen 1983; Iguchi et al.l993; Coe and 
Parks 1994; Taylor and Curhan 2004). Carbohydrates also stimulate endogenous 
synthesis of oxalate which is eventually excreted in urine (Lekcharoensuk et al. 2001 ). 
With high urinary concentrations of calcium and oxalate, the risk of forming stones is 
more pronounced as these are the main urinary CaOx risk factors. Therefore a low 
carbohydrate diet should be recommended to stone-forming patients. 
The effect of dietary sodium on CaOx stone formation has been studied mainly because 
of its calciuric action. Researchers are in agreement that for every increase in dietary 
NaCl of 100 mmol (i.e 2300 mg Na), there is an approximate increase of 1.0 mmol (40 
mg) in urinary calcium excretion (Lemann et al. 1995; Blackwood et al. 1999). Studies 
by Kok et al. (1990) and Shakaee et al. (1993) found that increasing dietary sodium 
chloride (from 14 to 310 mmol/day and 50 to 250 mmol/day respectively) increased 
urinary calcium by 34 % and 31 % respectively and decreased urinary citrate by 10 % 
and 20 % respectively. Thus, hypercalciuria and hypocitraturia are important lithogenic 
consequences of excessive intake of dietary salt, thereby increasing the risk of CaOx 
stone formation. 
Therefore CaOx stone formers are advised to decrease their sodium intake to less than 6g 
of dietary salt per day. Most patients can accomplish this by avoiding salty foods and salt 
shakers (Pak 2004 ). 
Fluid intake 
Increased fluid intake is of great importance in preventing urolithiasis (Pak et al. 1980; 
Borghi et al. 1996). This is because a low fluid intake leads to concentrated urine and 
increases the risk of stone formation. Thus, it is common practice to advise all stone 
forming patients, regardless of their stone type to consume between 2.5 and 3 litre of 





A urine volume of less than 1 litre a day is the only scientifically proven factor known to 
increase the risk of CaOx stone formation (Goldfarb 1990). 
Water is the best fluid to drink in order to avoid the risk of kidney stones (Krieg 2005) 
and mineral water is believed to be an ideal beverage to dilute the urine (Hesse et al. 
1993). Numerous studies have been undertaken on mineral water (rich in calcium, 
magnesium and bicarbonate) on either healthy subjects or patients with kidney stones by 
different researchers (Hesse et al. 1993, Rodgers 1997, 1998; Trinchieri et al. 1999; 
Siener et al. 2004; Karagillle et al. 2007). Water which is rich in magnesium and 
bicarbonate was found to increase inhibitory factors such as citrate and magnesium and to 
increase urinary pH as well. The same impact was observed for South African and French 
mineral waters which are rich in magnesium and calcium (Rodgers 1997, 1998). 
Even though the term 'fluid intake' in most cases implies water intake, other fluids like 
citrus juices are also recommended. These will be discussed in details in section 1.6 as 
they form a major part of this MSc dissertation. 
1.3 STATES OF SUPERSATURATION 
The physicochemical theory of stone formation involves supersaturated solutions and the 
effects of inhibitors and promoters of the fundamental mechanisms of stone formation, 
namely nucleation, growth and aggregation (Finlayson 1978; Rose 1982; Kok and Khan 
1994; Hess and Kok 1996, Coe et al. 2005). 
1.3.1 Fundamental role of supesaturation 
Supersaturation is a prerequisite for the occurrence of crystallization in urine (Finlayson 
1978). It is the thermodynamic driving force for the change of phase from solution to 
solid (crystallization) and it is a representation of excess free energy between the two 
phases (Hess and Kok 1996; Kavanagh 2006 (a)). As such, it is an important condition 
for renal precipitation and stone formation. This driving force or free energy (AG) is 
given by the equation 
AG=RT In (A/Aeq) 
where R is the gas constant, T is the temperature, A is the activity of the unionised salt in 




1978; Hess and Kok 1996; Kavanagh 2006 (a), (b)). (A/Aeq) is also referred to as relative 
supersaturaion (RS).Therefore, when RS < 1, the solution is said to be undersaturated 
and any stone forming salts that are present can freely dissolve. But when RS = I, the 
solution is saturated, and when RS >1, the solution is supersaturated. 
1.3.2 Thermodynamics of crystaUization 
Crysta11ization is the general term for the formation of crystalline material. The driving 
force for crystallization is the presence of supersaturation with respect to the composing 
salts. This is therefore referred to as the thermodynamic driving force of crystallization 
(Hess and Kok 1996). When this condition is met, the following kinetic mechanisms 
(nucleation, growth and aggregation) occur. These processes are all discussed below. 
Nucleation 
Nucleation is known as the initial phase transformation that leads to the formation of 
urinary stones (Finlayson 1978; Finlayson et al. 1984). This process occurs in a 
supersaturated solution. It starts with the clustering of stone salts in solution into loose 
conglomerates which can grow due to the decrease in free energy that is associated with 
change from liquid to solid phase (Finlayson 1978; Finlayson et al. 1984; Hess and Kok 
1996). 
Urine is rarely sufficiently concentrated to ensure a reasonable rate of spontaneous or 
homogeneous nucleation. Thus, it is probable that nucleation usually takes place on a 
foreign surface, i.e heterogeneous nucleation (Finlayson 1978; Finlayson et al. 1984; 
Hess and Kok 1996). 
Growth 
Once a crystal nucleus has reached its critical size, new crystal components are added to 
reduce the overall free energy. This mechanism is known as crystal growth. Crystal 
growth occurs due to 3 processes called speciation, bulk diffusion and adsorption. 
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Speciation refers to the binding of monomers to form complexes and these monomers 
migrate through the solution by a process called bulk diffusion. Bulk diffusion refers to 
the process in which the newly formed crystals travel through the solution and attach to 
the crystal by adsorption (Hess and Kok 1996). 
Aggregation 
Aggregation refers to the process whereby crystals combine to form a large particle under 
all states of satmation. There are two different types of aggregatio~ namely primary and 
secondary aggregation (Sohnel and Grases 1995). The primary aggregation represents a 
crystal malgrowth resulting in the formation of a polycrystalline particle while secondary 
aggregation proceeds by collision of particles suspended in the liquid induced by shear 
forces acting in the liquid. 
Crystal aggregation compared to nucleation and growth, is more important in the process 
of stone formation because CaOx growth is too slow to produce clinically significant 
particles within the transit time in the urinary tract, while aggregation occurs within 
seconds and is thus more dangerous for the formation of large crystalline particles in 
renal tubules (Kok et al. 1988; Hess and Kok 1996). 
1.4 URINARY RISK FACTORS 
Urolithiasis has long been recognised as the combined result of a number of individual 
determinant factors which are called biochemical risk factors (Robertson et al. 1978; 
Finlayson et al.1984; Hess and Kok. 1996). These risk factors can be considered as those 
determining the degree of supersaturation of urine, and affect the tendency of the crystals 
to enlarge and aggregate once nucleation and growth has occurred. The urinary risk 
factors which are measured in 24 hour urine samples are pH, volume, calcium, oxalate, 
uric acid, magnesium and citrate. Each of these risk factors is discussed below. 
1.4.1 Urinary pH 
Urinary pH is one of the most important risk factors of stone formation because it can 




An alkaline urinary pH reduces the risk of CaOx crystallization (Bilobrov et al. 1990; Pak 
1994). This is because phosphate and citrate ions dissociate at high pH, thereby 
increasing the complexation of calcium which lowers the urinary saturation of CaOx (Pak 
1994 ). But if hypercalciuria is present, then the increased complexation between calcium 
and phosphate that occurs with increasing alkalinity of the urine may increases the risk of 
CaP crystallization (Tiselius 1984) because CaP stone formation is most likely to occur at 
pH > 6 (Bilobrov et al. 1990). 
Thus, Tiselius ( 1981) has suggested that patients with hypercalciuria who are on 
therapeutic alkalanization, the therapy should be combined with calcium reducing 
measures to avoid brushite stone formation. 
On the other hand, a pH less than 5.5 may promote uric acid stone formation because of 
the predominance of the undissociated uric acid (Bilobrov et al. 1990; Tiselius 2003). 
It is therefore advisable to maintain the urinary pH between 6 and 7 because this range 
exhibits high inhibition of CaOx crystallization and uric acid formation (Bilobrov et al. 
1990). 
1.4.2 Urine volnme 
Urine volume is also extremely important in the pathogenesis of urolithiasis. A high 
urinary volume reduces the relative supersaturation of the crystal components in urine as 
a consequence of dilution effects. In addition, a high urinary volume leads to high urine 
flow rates, which will flush out the crystals that have formed in the urinary tract. As a 
result, high fluid intake has been the recommended treatment for kidney stones (Pak et al. 
1980; Borghi et al. 1996; Borghi et al. 1999). In a study by Pak et al. ( 1980), in which 
they investigated the effect of diluting urine, they found that a high water intake could 
inhibit the formation of kidney stones by reducing the saturation of calcium salts. 
A randomized clinical trial which lasted 5 years by Borghi et al. ( 1996) also 
demonstrated the value of increasing urine volume. In that study, stones recurred in only 
12 of the 99 patients who maintained a urine volume of about 2.6 Llday over 5 years, 
while stones recurred in 27 of the 100 patients in the control group whose urine volume 




As mentioned before in section 1.2, fluids other than water can be consumed to achieve a 
higher urinary volume. These include among others, citrus juices which will be discussed 
in detail later in this thesis, and herbal teas (Hesse et al. 1993). Because of an increase in 
the supersaturation of stone forming salts due to low volume of urine, stone forming 
patients should be advised to drink more fluids in order to achieve a mine output of 2 or 
more litres a day. However, other fluids that must be avoided are those with high oxalate 
content, for example cola (Weiss et al. 1992; Rodgers 1999 (a)) and hot chocolate and 
large amounts of tea (Hesse et al. 1993 ). Other fluids which must be avoided as they 
increased the risk of kidney stones include apple juice and grapefruit juice (Curhan et al. 
1996). 
1.4.3 Urinary calcium 
Hypercalciuria occurs to a greater extent in stone formers as compared to normal controls 
(Heilberg 2000; Curhan et al. 2001) and is induced in about half of recurrent kidney stone 
formers (Morton et al. 2002). It is a risk factor for recurrent stone formation (Coe et al. 
1982; V ahlensieck 1986; Goldfarb 1994; Borghi et al. 1996). A normal upper limit for 
24h urinary calcium excretion of7.5 mmol and 6.5 mmol in men and women respectively 
has been reported (Monk 1996; Bihl and Meyers 2001 ). For many years, hypercalciuria 
was regarded as one of the most important factors that contribute to a high 
supersaturation of CaOx urolithiasis (Marshall et al. 1972; Bleich 1979~ Vahlensieck 
1986; Rose 1987). However, as described earlier, it is urinary oxalate which is more 
important in the formation of CaOx crystals than calcium (Borsatti 1991 ). Because 
hypercalciuria is common, a moderate calcium intake of 1 g/day may be a reasonable 
recommendation for CaOx patients (Morton et al. 2002). 
1.4.4. Urinary oxalate 
Oxalate is a dicarboxylate anion which forms an insoluble salt with calcium in urine. It is 
the end product of several metabolic pathways, including those involving serine, glycine, 
hydroxyproline and ascorbate. (Morton et al 2002). It is by far the most critical 
determinant of stone prevalence compared to other risk factors like hypercalciuria, 
hyperuricosuria and hypocitraturia (Ito et al. 1989; Borsatti 1991; Ito et al. 1992). 
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There is much less oxalate than calcium in urine; therefore small increases in oxalate 
concentration have a far greater impact than changes in calcium concentrations. A study 
by Rodgers ( 1999 (b)) has demonstrated this by showing that the rate of change in 
supersaturation is 23 times greater for increased oxalate than for comparable increases in 
calcium. 
Various mechanisms have been identified for increases in urinary oxalate excretion. 
Firstly, an increased dietary intake allows more oxalate to reach the colon, increasing its 
availability for absorption (Robertson 1999). A second mechanism is an increased 
endogenous production of oxalate (Massey et al. 1993). Finally a deficiency in oxalate-
degrading bacteria (Allison et al. 1986, Sidhu et al. 1999) particularly Oxalobacter 
formigenes has been suggested as causing an increase in the risk ofhyperoxaluria. 
1.4.5. Urinary uric acid 
High urinary excretion of uric acid (hyperuricosuria) is a risk factor for uric acid and 
CaOx stone formation. Two possible mechanisms have been suggested for the elevation 
of urinary uric acid: excessive intake of dietary protein and endogenous overproduction 
of uric acid (Coe 1978). It is most commonly caused by increased purine intake in the 
diet (Halabe and Sperling 1994; Porena et al. 2007). On the basis of the observation that 
approximately one third of CaOx stone formers have elevated urinary uric acid excretion 
(Coe 1978), elevated excretion of urinary uric acid has been proposed as a risk factor for 
the nucleation, growth and aggregation of CaOx crystals (Robertson et al. 1978 (b); 
Griffith et al. 1986). 
Treatment with allopurinol blocks uric acid production and decreases the recurrent rate of 
CaOx kidney stones in patients with hyperuricosuria (Pak 1978; Ettinger 1991), even 
though this treatment has no effect on urinary calcium or oxalate saturation (Baggio et al. 
1983; Tiselius et al. 1986). 
1.4.6 Urinary magnesium 
Several decades ago it was established that magnesium can decrease the crystallization of 
CaOx by complexing with oxalate ions to form soluble magnesium oxalate, thus reducing 
15 
CfupterOne 
the amount of free oxalate in the urine (Desmars and Tawashi 1973; Hallson et al. 1982). 
It is this capacity of magnesium to chelate oxalate that makes it an inhibitor of CaOx 
crystallization. This is advantageous since, as mentioned earlier, oxalate has a far greater 
impact in CaOx stone formation than calcium. 
1.4.7 Urinary citrate 
Hypocitraturia is a major risk factor for kidney stones (Morton et al. 2002; Porena 2007). 
Several studies have demonstrated hypocitraturia in stone formers (19-63 %), thereby 
showing its importance in the pathogenesis of this disease (Rudman et al. 1982; Nicar et 
al.1983; Pak et al. 1985; Laminski et al. 1990; Cupisti et al. 1992). 
It is caused by high animal protein diet which leads to reduction of urinary citrate (Pak 
2004). Other causes for hypocitraturia are distal renal tubular acidosis, and metabolic 
acidosis of chronic diarrheal syndrome (Pak 2004). Hypocitraturia increases urinary 
saturation of CaOx by impairing the formation of calcium citrate complex [ CaCit] -I. It 
also promotes nucleation and aggregation of CaOx and crystal growth of CaP (Pak 2008 
(b)). 
Hypocitraturia can be treated, and stone patients with this disorder are recommended to 
undergo alkali therapy (Parks and Coe 1986; Conte et al. 1989 (a)) which includes the 
intake of K-citrate or Na-K-citrate supplements (Pak et al. 1983, 1985; Porena et al 
2007). Not only can therapy be used to treat hypocitraturia, but also citrus fruits/juices 
have been found to be of importance with respect to treatment of stones. As mentioned 
before, this topic will be discussed fully in section 1.6 of this Chapter. 
1.5 URINARY INHIBITORS 
An inhibitor is any substance, molecule, ion or agent that slows down or prevents 
nucleation, growth or aggregation of calcium salts in urine (Kok 1996; Worcester 1996; 
Ryall 1997). They may act by complexing either calcium or oxalate ions, thereby 
reducing the level of CaOx supersaturation in the crystallizing solution. 
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Urinary inhibitors can be categorised into micromolecules which include: multivalent 
metallic cations (e.g magnesium), small organic (e.g citrate) or inorganic (e.g 
pyrophosphate) anions and macromolecules such as glycosaminoglycans and proteins 
(Worcester 1996; Moe 2006). 
1.5.1 MICRO-INHIBITORS 
Magnesium: Magnesium has been shown to decrease the crystallization of CaOx by 
complexing with oxalate ions to form soluble magnesium oxalate. This means that 
magnesium can reduce the amount of free oxalate ions in the urine (Desmars and 
Tawashi 1973; Hallson et al. 1982; Danielson 1985). This is favourable because as 
mentioned earlier, oxalate is the determining factor in CaOx formation. Studies have 
shown that magnesium lowers the urinary saturation, decreases nucleation and growth of 
CaOx and even CaP crystals (Kohri et al. 1988; Grases et al. 1989 (a); Lindberg et al. 
1990; Pak et al. 1992). 
Pyrophosphate: Pyrophosphate inhibits nucleation of CaOx crystals (Grases et al. 1989 
(b); Ryall 1997), causes some inhibitory effects of crystal growth (Grases et al. 1989 (c); 
Conte et al. 1989 (b)) and is a strong inhibitor of aggregation of CaOx crystals 
(Robertson et al. 1973; Robertson et al. 1974; Felix et al. 1977). It inhibits these 
processes by binding calcium in its solid phase. It irreversibly binds to COM crystal 
surfaces and not to COD (Shirane and Kagawa 1993; Wesson et al. 1998). This is of great 
pathological importance since COD crystals are less adherent to renal epithelial cells than 
COM crystals, thus potentially inhibiting a critical step in the genesis of kidney stones 
(Shirane and Kagawa 1993; Wesson et al. 1998). 
Citrate: Citrate is an important urinary acid neutralizer and it is a naturally occurring 
urinary stone inhibitor that chelates calcimn in solution, forming a highly soluble 
calcium-citrate complex that decreases ionic concentration of calcium, thereby decreasing 
the RS of CaOx and CaP in urine (Preminger et al. 1985; Pak et al. 1985). 
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It also inhibits their crystal nucleation, growth (Ryall et al. 1981; Pak 1987; Grases et al. 
1989 (c); Grases and Costa-Bauza 1990; Conte et al. 1990; Laube et al. 2002) and 
aggregation (Kok et al. 1 987; Tiselius et al. 1993 (a) and (b)). 
Citrate is derived from both endogenous (tricarboxylic cycle) and exogenous sources 
(citrus fruits) (Morton et al. 2002). 
Supplemental citrate 
Supplemental citrate is the most common therapeutic agent that is used to prevent 
calcium and mic acid stones. The inhibitory potency of citrate depends on its ability to 
alkalinize urine and to form complexes with calcium. Such complexation reduces urinary 
supersaturation for CaOx and CaP and retards the nucleation, growth and aggregation as 
well as agglomeration of preformed CaOx crystals (Pak and Fuller 1983; Kok et al. 1986; 
Laube et al. 2002; Byer and Khan 2005). 
The therapeutic effects of various different citrates on CaOx crystallization inhibition 
have been tested. Potassium citrate is the most common supplementation as it has been 
demonstrated to increase urinary citrate levels, and decrease urinary calcium excretion 
and relative supersaturation with respect to CaOx (Sakhaee et al. 1983; Pak et al. 1985; 
Preminger 1988; Hofbauer et al. 1994; Whalley et al. 1996; Sellmeyer et al. 2002). 
Other citrate salts that have been tested include sodium citrate (Sakhaee et al. 1983, Allie-
Hamdulay and Rodgers 2005), magnesium citrate (Schwille et al. 1999), potassium-
magnesium citrate (Pak et al. 1992; Ettinger et al. 1997), calcium citrate (Sakhaee 2005), 
calcium-sodium citrate (Schwille et al. 1997) and sodium-potassium citrate (Achilles et 
al. 1990; Hofbauer et al. 1994 ). 
Some of these therapies have shown 60 to 96 % reduction in kidney stone recurrence 
(Pak and Fuller 1983; Pak et al. 1985, Pak and Peterson 1986; Ettinger et al. 1997). 
However, even though the alkali citrate therapy showed some reductions on CaOx stones, 
it can be a burden as some patients experience gastric side effects and financial 




In the context of urolithiasis, 'macromolecules' refer to urinary glycosaminoglycans and 
proteins. Numerous studies have shown that normal urine contains macromolecular 
substances that are capable of preventing and reducing CaOx crystal formation and 
aggregation (Boyce 1968; Morse and Resnick 1989; Jones and Resnick 1990; Ryall 2000; 
Khan and Kok 2004 ). 
Glycosaminoglycans (GAGs) 
GAGs are polysaccharides which are composed of repeating disaccharide units (Roberts 
and Resnick 1986). They have a varying molecular weight of 18-40 kDa and account for 
20 % of the matrix of stone. Although there are in vitro studies which have demonstrated 
that they inhibit growth and aggregation of CaOx crystals (Roberts and Resnick; Ryall 
1997; Khan and Kok 2004), some studies have demonstrated that GAGs promote 
nucleation and growth rate (Kohri et al. 1989). 
Urinary proteins 
The organic matrix of kidney stones comprises 2.5 % of dry weight containing lipids, 
carbohydrates and proteins. The latter comprise 64 % of the stone matrix itself (Boyce 
and Garvey 1956). Albumin, a and y-globulin and Tamm-Horsfall Protein (THP) were 
the first proteins to be identified in the stone matrix (Boyce et al. 1968), while other 
proteins including nephrocalcin, osteopontin, albumin, urinary prothrombin fragment 1 
{UPTF1), inter- a- trypsin inhibitor and bikunin have been identified to be having a role 
in the inhibition and promotion of CaOx crystallization (Rose et al. 1982; Nakagawa et 
al. 1983; Coe et al. 1991; Doyle et al. 1991 ; Ryall et al. 1991 ; Atmani et al. 1993; Hess et 
al. 1993; Worcester and Beshensky 1995; Grover et al. 1998; Fries and Blom 2000; 
Webber et al. 2002; Yang et al. 2005). 
Nephrocalcin: Nephrocalcin is a glycoprotein with a molecular weight of ~ 14 kDa. It 
has been reported to self-aggregate into large molecules that range from 23-68 kDa 
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(Worcester et al. 1987). Nephrocalcin has been demonstrated to inhibit the crystal 
formation and aggregation as well as being able to prevent attachment of crystals on the 
surface of renal epithelial cells (Nakagawa et al. 1983). 
Osteopontin: Osteopontin was originally isolated as a glycoprotein with molecular 
weight of 50 kDa (Khan and Kok 2004). It is found in urine, human CaOx stones, CaOx 
and CaP crystals grown in human urine (Worcester 1996; Wesson et al. 1998). 
Osteopontin can modulate CaOx crystallization by inhibiting crystal nucleation, growth 
and aggregation (Worcester 1996; Wesson et al. 1998). 
Tamm-Horsfall Protein (fHP): THP is the most abundant protein in human urine with 
molecular weight of 80-1 OOkDa (Ryall 1997). It is produced in the kidney and specially 
localized in the epithelial cells of the loop of Henle. Some studies report that THP 
inhibits and promotes CaOx crystallization depending on the experimental conditions 
(Hess 1994; Grover et al. 1998) while others have reported that THP can inhibits 
nucleation and aggregation ofCaOx and CaP crystallization (Rose et al. 1982). 
Albumin: Albumin has also been classified as the most abundant protein in the urine 
(Hess et al. 1989; Grover et al. 1998). It is manufactured in the liver and has been 
detected as the major component in the matrix of all urinary stones (Boyce 1968). It has 
been shown to promote CaOx nucleation but inhibits CaOx crystal aggregation (Grover et 
al. 1998; Worcester 1996; Khan and Kok 2004). 
Prothrombin Fragment 1 (UPTFl ): UPTFl is a protein with a molecular weight of 31 
kDa This protein is found in calcium stones and also located in greater quantities in the 
human kidney of the stone formers (Doyle et al. 1991, 1995). It was found to be an 
effective inhibitor of CaOx growth and aggregation in ultrafiltered urine (Ryall et al. 
1995; Doyle et al. 1991 ). 
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1.6 CITRUS FRUITS AND JUICES 
Dietary citrate has been shown to play an important role in urolithiasis. Citrus fruits and 
juices represent a naturally rich source of citrate and provide a dietary citrate load 
equivalent to that of citrate supplements (Seltzer et al.1996). Such fruits include lemon, 
orange, grapefruits and lime (Wabner and Pak 1993; Seltzer et al. 1996; Trinchieri et al. 
2002; Tosukhowong et al. 2008). These citrus fruits/juices may be important in the 
treatment of hypocitraturia and the management of CaOx or CaP stone patients, who may 
not be able to tolerate commercial therapy which requires the ingestion of several tablets 
or liquid supplements daily or who cannot bear the inherent financial burden associated 
with these preparations (Seltzer et al.1996). 
As mentioned previously, citrus fruits/juices are a well-known natural source of citrate 
and therefore could represent an alternative to phannacological citrate therapy. Several 
studies have investigated the impact of citrus juices on urinary parameters and have 
indeed shown that they have a positive effect towards hypocitraturia and CaOx crystal 
formation. 
The advantage of citrus juices is that they are better tolerated and they are less cost 
effective than pharmacological treatments. In addition to this, some reports have shown 
the dropout rates of K -citrate due to the inconvenience of multiple administrations and 
the gastrointestinal intolerance (Pak et al. 1985; Schwille et al.l992; Barcelo et al. 1993, 
Hofbauer et al. 1994). This is supported by a recent review by Mattie and Hess (2005) 
which stated that up to 48 % of alkali citrate-treated patients withdrew prematurely from 
the studies because of intolerable side effects. 
1.6.1 Grapefruits, Orange, Blackcurrant and Cranberry juices 
Trinchieri et al. (2002) showed that the ingestion of grapefruit juice in healthy subjects 
caused an increase in urinary citrate, calcium and magnesium excretion. In another study, 
Honow et al. (2003) showed that apart from an increase in urinary citrate excretion, 
urinary pH also increased after the ingestion of grapefruit juice and hence the RS of 
CaOx decreased. Orange juice has also been investigated (Wabner and Pak 1993; Honow 





increasing urinary pH and citrate excretion. Similar results have been reported for 
blackcurrant juice (KeBler et al. 2002). 
In all of these studies, urinary citrate excretion was increased. It is because of these 
results that investigators are convinced that citrus fruits can be used as a pharmacological 
therapy. 
However, not all of the studies have produced entirely favourable results. Goldfarb and 
Asp lin (200 1) in their study showed that the ingestion of 240 ml of grapefruit juice 3 
times a day by healthy subjects resulted in an increase in citrate excretion but that urinary 
oxalate also increased. Furthermore, in two studies involving cranberry juice, urinary pH 
decreased, there was no affect on urinary citrate excretion, while urinary calcium and 
oxalate increased thereby increasing urinary saturation of CaOx and uric acid (KeBler et 
al. 2002; Gettman et al. 2005). However, the acidification of urine by cranberry juice was 
suggested to be useful in the treatment of brushite and struvite stones as well as in the 
treatment of urinary tract infections. 
The unfavourable results reported by KeBler et al. and Gettman et al. are in contrast to 
those reported by McHarg et al. (2003) who showed that cranberry juice favourably 
altered 3 key urinary risk factors namely, oxalate and phosphate excretion (which 
decreased) and urinary citrate (which increased). It is therefore apparent that the potential 
therapeutic value of the above-mentioned group of juices has not been convincingly 
demonstrated. 
1.6.2 Lemon juice 
Several studies have investigated the effects of lemon juice in stone forming patients 
(Seltzer et al. 1996; Koff et al. 2007; Kang et al. 2007; Penniston et al. 2007; Aras et al. 
2008). Lemons contain high concentrations of citric acid (Seltzer et al. 1996). Thus, a 
half cup of pure lemon juice can provide a daily amount of citrate comparable to that of 
pharmacological therapy (Seltzer et al. 1996). The above mentioned studies (Seltzer et al. 
1996; Kang et al. 2007; Penniston et al. 2007; Aras et al. 2008) showed that the ingestion 
of lemon juice increases the urinary excretion of citrate, while that of Koff et al. (2007) 
showed that lemon juice did not provide improvements in urinary citrate or pH. 
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They also showed increased urinary pH and decreased calcium levels. Because of the 
improvement in the urinary parameters of citrate and/or pH after the ingestion of lemon 
juice in either healthy subjects or kidney stone patients, it can be concluded that lemon 
juice may be of great importance in the treatment of urolithiasis. 
1.6.3 Lime joice 
Lime (citrus auranlifolia), is a wild species originally from the Rutaceae family and it is 
common in Southeast Asian countries (Tosukhowong et al. 2008). It is rich in citrate as 
well as various antioxidants such as ascorbic acid, polyphenols and flavonoids 
(Gharagozloo et al. 2002). It is inexpensive and is used as a routine cooking ingredient, 
fruit, juice, preserved snack and as a medicinal agent (Wagner and Wu 2002; Xu et al. 
2003; Bailey et al. 2003 ). 
The effect of lime juice consumption on urinary pH was investigated by Mazdak et al. 
(2006). It was found that urinary pH increased. The authors suggested that its 
consumption can support treatment and prevention of uric acid and cystine stones as well 
as management of gout due to its alkalizing effect. 
Tosukhowong et al. (2008) investigated the effects of lime powder ingestion in CaOx 
nephrolithiasis patients. They found a significant elevation of urinary citrate, potassium 
and pH while calcium and oxalate were unaltered. These results showed that lime 
delivers an antilithogenic action for treating nephrolithiasis that is equivalent to that of 
standard potassium citrate. 
1. 7 UROLITHIASIS IN SOUTH AFRICA 
As mentioned before, the incidence of kidney stones in the South African black 
population is extremely rare compared to the white population. Even though there has 
been a slight increase in the incidence of kidney stones in urban blacks in recent years, it 
still occurs in less than 1 % of this group, but in 12-15 % of the white population (Muskat 
1951; Modlin 1967; Pantanowitz et al. 1973; Meyers et al. 1994; Whalley et al. 1998). 
The prevalence of stones in whites is similar to those in Western countries (Modlin 1967; 
Whalley et al. 1998). 
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Factors such as those discussed earlier in this chapter, as well as others, are likely to 
contribute to the rarity of stones in the black South African population group. 
1.7.1 Urine chemistry 
Several studies have compared urine composition data of South African black and white 
subjects in order to identify differences which might account for the rarity of stones in the 
former group (Modlin 1967; Meyers et al. 1994; Whalley et al. 1998; Lewandowski et al. 
2005). 
Urinary calcium has been consistently reported as being lower in black subjects 
compared to whites (Modlin 1967; Meyers et al. 1994; Whalley et al. 1998; Rodgers and 
Lewandowski 2002; Charlton et al. 2005). Urinary citrate excretion has been reported as 
being lower in the black group (Modlin 1967; Meyers et al. 1994; Whalley et al. 1998; 
Lewandowski et al. 2001 ). Reports have also shown that urinary sodium excretion in 
black subjects is higher than that in whites (Modlin 1967; Meyers et al. 1994). 
Urinary pH and phosphate have been reported to be lower in blacks (Modlin 1967; 
Lewandowski et al. 2001). Intriguingly, no differences in urinary oxalate have been 
reported in most of these studies. However one study found this variable to be higher in 
the black group (Lewandowski et al. 2001 ). Some of these results are surprising and 
counterintuitive (lower citrate, lower pH, higher oxalate) because they suggest that black 
subjects have a higher risk of CaOx stone formation than white subjects. 
On the other hand, while lower urinary calcium and phosphate levels occur in black 
subjects, they nevertheless lie within the normal range. Thus, while these differences 
could account for a lower prevalence of stone disease in the black group, they cannot 
account for the absence of the disease. 
1.7.2 Diet 
Studies in the Kidney Stone Laboratory at the University of Cape Town as well as those 
by others have shown that the South African black population has a dietary intake that is 
high in oxalate, (because of regular intake of spinach) (Viljoen and Gericke 2001 ), low in 
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calcium because oflactose intolerance (Viljoen and Gericke 2001; Charlton et al. 2005), 
low in magnesium (Whalley et al. 1998; Charlton et al. 2005) and low in vitamin B6 
(Lewandowski et al. 2001 ). 
As with urine composition studies, these results are surprising and counterintuitive as all 
of these eating habits are risk factors for hyperoxaluria However, notwithstanding these, 
urinary oxalate in this race group has been shown to be within the normal range (Whalley 
et al. 1998; Rodgers and Lewandowski 2002; Lewandowski et al. 2005). 
On the other hand, investigators have shown that South African blacks have a diet that is 
high in sodium compared to whites (Modlin 1967; Meyers et al. 1994; Whalley et al. 
1998). As mentioned before about dietary sodium, hypercalcuria is an important 
lithogenic consequence of excessive intake of dietary salt and this increases the risk of 
CaOx stone formation (Pak 2004). It is therefore somewhat surprising that urinary 
excretion of calcium in blacks has been found to be lower. In order to explain these (and 
other) dietary anomalies, it has been suggested that the South African black group may 
have different mechanisms for handling lithogenic agents than the white population 
group (Lewandowski et al. 2001; Rodgers and Lewandowski 2002). 
1.7.3 Proteins and microbiological activities 
Urinary proteins are well known as macromolecular inhibitors of urolithiasis. Studies at 
the Kidney Stone Research Laboratory (University of Cape Town) have investigated the 
inhibitory role of several urinary proteins in the two race groups. These include urinary 
prothrombin fragment 1 (UPTFI) (Webber et al. 2002). Tamm-Horsfall mucoprotein 
(TIIM) (Craig et al. 1999, 2001) and Albumin (Rodgers et al. 2006). 
Studies on UPTFI showed that it is an inhibitor of CaOx crystallization and that the 
protein isolated from the urine of blacks was superior to that obtained from whites in this 
regard (Webber et al. 2002). The authors suggested that the urine composition of blacks 
may influence their UPTFI conformation in such a way that it performs better as an 
inhibitor than when it is in the urine milieu of white subjects (Webber et al. 2002). 
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Similarly, THM protein was isolated from the urine of both race groups and was found 
that the protein from black subjects was a stronger inhibitor of CaOx crystal aggregation 
than that obtained from white subjects (Craig et al. 1999, 2001). 
Finally, in another study, albumin was also isolated from both groups and found to be a 
superior inhibitor of CaOx crystal growth and aggregation in black subjects (Rodgers et 
al. 2006). 
Another factor which is of interest is the gastrointestinal absorption of oxalate which was 
measured by Lewandowski et al. (2005). No difference between these two race groups 
was found despite the fact that blacks have a higher dietary intake of oxalate. This might 
be due to the lower endogenous synthesis of oxalate in blacks. The other possible 
explanation is that blacks may excrete more calcium into the intestine thereby stopping 
more gastrointestinal oxalate being bound and thus excreted via the faeces (Lewandowski 
et al. 2005). A more JikeJy explanation is that South African blacks have greater 
colonization of oxalate-degrading bacteria (Lewandowski PhD Thesis, 2003) than whites, 
hence less oxalate available for gastrointestinal absorption and urinary oxalate. 
OVERVIEW 
The empirical evidence presented in section 1.7 strongly suggests that the handling of 
lithogenic and antilithogenic agents by South African black subjects is different to that 
which occurs in their white compatriots. While there are many such agents which still 
remain to be investigated, lime powder was selected for study in the present MSc project 
with a view to exploring whether it too is handled differently in the two population 
groups and if so, whether these differences might contribute towards understanding why 
stone rarity occurs in the one group but not in the other. 
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1.8 OVERALL AIM AND OBJECTIVES 
The overall aim of the present study was to investigate the handling of lime powder 
ingestion in subjects from South Africa's two population groups, with a view to gaining 
insight into why the incidence of urolithiasis is different between them. 
The individual objectives to achieve this overall aim were: 
(i) to measure the inhibitory activity of lime powder in artificial urine. 
(ii) to measure the relative inhibitory activity of lime powder after its in vitro 
introduction into the voided urine of healthy black and white South African 
subjects. 
(iii) to measure and compare urinary risk factors in the two race groups before and 
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This chapter describes the methods that were used in the different studies Wldertaken for 
this dissertation. 
Experiments commenced with the preparation of artificial urine (AU). The inhibitory 
effects of lime powder on CaOx crystallization in vitro were investigated using different 
crystallization experiments. 
Also described in this chapter are the experiments and risk indices used to determine 
and/or measure the inhibitory activity of lime powder towards CaOx crystallization in the 
trial study. 
2.2METHODS 
2.2.1 Manufacture of lime powder 
Lime powder was obtained from Thailand as part of a collaborative agreement between 
the Kidney Stone Research Laboratory (University of Cape Town) and a research group 
at Chulalongkom University, Thailand. The powder was derived from natural lime, citrus 
auranlifolia. Lime fruits from local orchards in the central region of Thailand were 
harvested and were then thoroughly washed, cut in half and squeezed with a hand-
squeezer to yield fresh lime juice. The seeds were filtered out and the lime juice was 
processed to reduce bitterness (Y achantha et al. 2007; T osukhowong et al. 2008). 
Methods describing how bitterness was reduced are not available. 
The lime juice was then freeze-dried using a freeze dryer (Model FDS, Heto-Holten AS, 
Denmark). Its chemical composition is given in Table 2.1 (Yachantha et al. 2007). The 
composition and physical characteristics (colour, odour and flavour) resembled that of the 
original lime (T osukhowong et al. 2008). Aluminium sachets containing five grams of 
lime powder were packed and completely sealed. 
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Table 2.1: Chemical composition of lime powder (Yachantha et al. 2007) 




Total Na 1.32 
Total K 102.74 
TotalMg 0.24 
Total P 0.815 
Total Ca 15.59 
Ascorbic acid 27.30 
Total polyphenols 9.20 
Flavonoids 8.80 
2.2.2 Preparation of Artificial Urine (AU) 
Artificial urine (AU) was prepared according to the method of Walton et al. (2005). A 
standard solution of 320 mM of NaCl, 99.5 % (Orion Chemicals), 50 mM NaH2P04 
99.102 %, (Merck), 6.52 mM MgCh, 99 % (Riedel-de Haen), 164.2 mM KCl, 99.5 % 
(Merck), 4.34 mM K3Citrate, 99% (Merck), 43.8 mM (NI-4)2SO.., 99.5% (Merck), 7.0 
mM NlLtCl, 99.5% (Merck) was prepared using distilled water in appropriate volume. 
The pH of the solution was adjusted to 6.0 using 5 M of NaOH and the solution was 
stored at 4 ·c wrtil it was ready to be used. The solution was warmed at 37"C and filtered 
(0.22 JlDl) immediately before use. Two solutions of 50mM Na20x, 99.5 % (Associated 
Chemical Enterprises c.c) and 120 mM CaCh, 95% (Merck) were prepared separately 
and filtered (0.22 JlDl). 1780 J.Ll of the 120 mM CaCh solution and 286 J.Ll of the 50 mM 
Na20x solution were mixed to achieve final concentrations of2.14 mM and 0.143mM for 
calcium and oxalate respectively. 
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2.2.3 Subjects, uriue coUection, treatment and physicochemieal properties 
South African black and white healthy males with no history of kidney stone formation 
participated in the in vitro and clinical trial studies described in this dissertation. Subjects 
were excluded if they were on any medication that would interfere with the studies and 
they were asked to stop taking their vitamin supplements three days before they 
commenced with each study. 
24 hour urine samples were collected in plastic bottles without preservative from 5 black 
and 5 white healthy male subjects (age range 18-32 years) on their free unrestricted diets. 
Each sample was tested for haematuria and nitrite using urinalysis test strips (Medi Test 
Combi SN, Macherey-Nagel; DOren). Those that tested positive for either were discarded. 
All urine samples were analysed for pH, sodium, potassium, calcium, oxalate, urate, 
citrate, chloride, magnesium, phosphate and creatinine as described below. 
pH was measured using a Microprocessor pH meter (Hanna Instruments). Sodium, 
potassium, magnesiwn and calciwn were determined using atomic absorption 
spectroscopy (Varian 1275 Model; Australia) (Willis 1969. Trudeau and Freier 1967; 
F emandez and Kahn 1971) while commercially available assay kits from Sigma Aldrich 
and Boehringer Mannheim were used for oxalate (Chiriboga 1963) and citrate, 
respectively (Gruber and Mollering 1966). Chloride was determined using a chloride 
sensitive electrode (Beckman Coulter Inc). Creatinine was determined using picric acid 
(Rock et al. 1986). Phosphate was determined using ammoniwn molybdate while urate 
was determined using uricase (Synchron LX assay kits, Beckman Coulter Inc) (Fossati et 
al. 1980). 
2.2.4 Crystallization Experiments 
CaOI Metastable Limit (MSL) 
Urine samples were prepared for determination of the CaOx metastable limit (MSL) by 
filtering successively though a 0.75 J.lm pre-filter (Macherey-Nigel; GmBH and Co., 
Germany) and 0.45 J.lm nitrocellulose filter (Sartorius AG, Germany). The MSL of each 
sample was determined following the method described by Ryall et al. (1985). 
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Thirteen aliquots (10 ml) of each sample were added to Coulter cups and incubated at 
3rC- in a shaking water bath at 100 rpm (Labmark, Johannesburg) for 10 minutes. Each 
aliquot was then successively dosed with 100 JJ.l of sodium oxalate (Na20x) of increasing 
concentrations (15 mmol/L to 195 mmol/L) and incubated for a total of30 minutes each. 
The particle number and volume in each aliquot were measured using a Coulter 
Multisizer II (Coulter Electronics Ltd, Luton, UK) fitted with a 140 J.1ID orifice (2.8-90 
1-1m particle size range). 
The concentration of Na20x corresponding to the dose which caused a sudden increase in 
particle number was regarded as a measure of the MSL of the particular sample under 
investigation. A representative curve which shows the determination of the MSL is shown 
in Figure 2.1 . The final Na20x concentration corresponding to the metastable limit is 
indicated by a red point. 
Typical Metastable Limit Plot 
15 30 45 60 75 90 105 120 135 150 165 180 195 
[Na20 x] (~moUI) 
Figure 2.1: A typical example of a MSL graph. 
CaOx Particle Size-Volume Distributions (PSD) 
Once the MSL had been determined, 50 ml of each urine sample was incubated in soda-
lime bottles in a shaking water bath (Labmark, Johannesburg, 100 rpm) at 37 OC for 10 
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minutes. An aliquot of 10 % (v/v) Na20x corresponding to 30 mmoi/L above the 
previously determined MSL was then added to the sample to induce crystallization. 
Thereafter the samples were incubated for two hours and the total volume of particles 
precipitated during the incubation period and the mean particle size were determined 
using the Coulter Multisizer II mentioned previously. Graphs of particle volume vs 
particle size were constructed. The mode of the curve represents the mean size of 
precipitated particles, while the total volume of precipitated particles is represented by the 
total area under the curve. A typical volume vs size graph is shown in Figure 2.2. 
Particle Volume -Size Distribution (120min) 
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Figure 2.2: A typical example of volume vs size graph 
Scanning Electron Microscopy (SEM) 
All urine samples were dosed with aqueous Na20x as described in the previous paragraph 
before being examined by scanning electron microscopy. 
At the end of the 2 hour incubation peri~ 2 ml of the dosed urine was filtered through 
0.22 J.lm filters and dried at room temperature. Once the filter papers were dry, they were 
mounted on aluminium stubs using Sticky Tabs (ProSciTech, Thailand). The deposited 
crystal were viewed using a Leica S440 scanning electron microscopy (Leica Cambridge 
Ltd, England) operating at an accelerating voltage of 10 KV, a working distance of 1 0-15 
mm and a probe current of20-30 pA. 
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Micrographs for different sets of experiments were always recorded at the same 
magnification so that valid comparisons could be made, but the actual magnification 
varied for the different studies. 
The procedure in which SEM was used to view crystals after the urine samples had been 
dosed was adopted because natural undosed samples in all experiments did not reveal 
crystals large enough to be visualised by SEM. Despite this exogenous method for 
producing crystalluria, comparisons of different samples in this way were regarded as 
being valid and appropriate, as all urines were treated in the same way. 
Simultaneous measurements of CaOx crystal nucleation and aggregation inhibition 
Crystal nucleation and aggregation were induced and monitored according to the 
procedure described by (Hess et al. 1995). Stock solutions of 8.5 mmol!L of CaCh and 
Na20x (1.0 mmol/L) each containing 200 mmol/L and 10 mmol/L sodiwn acetate 
respectively, were prepared and the pH was adjusted to pH 5.7 by using 5M NaOH. The 
stock solutions were filtered through a 0.22 ~ filter to remove any debris that might 
interfere with the spectrophotometric measurements. 
The experiment was performed in a circulating water bath at 37 OC. CaCh solution (1 ml) 
was transferred into a I 0-mm cuvette placed in a spectrophotometer (Analytikjena, 
Specord 40, German), regulated at 37 °C and constantly stirred at 500 rpm. 1 ml of the 
Na20x solution was added to the CaCh solution, resulting in final assay concentrations of 
4.25 mmol/L calcium and 0.5 mmol/L oxalate, respectively. The automated time course 
measurement of OD62o was performed after the addition of N820x solution to the CaCh 
solution. These values were recorded every 0.5 seconds for 60 minutes. 
The maximum increase in the slope of OD620 with time is interpreted as representing the 
maximum rate of formation of new particles, i.e rate of crystal nucleation and is termed 
(SN), while the decrease in the slope of OD62o with time is interpreted as representing 
crystal aggregation and is termed (SA) (Hess et al. 1995). A typical crystal nucleation and 
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Figure 2.3: A typical plot of absorbance vs. time for the determination of CaOx · 
nucleation and aggregation assays. 
The experiment was performed in (i) AU alone, (ii) real urine alone, (iii) AU + lime 
powder and (iv) real urine + lime powder. The urine samples were tested at a ratio of 
800J.11 of CaCh: 400 J.11 of urine: 800 J.11 of Na20x. OD62o was recorded every 0.5 seconds 
over 60 minutes. This urine concentration of 400 J.1l urine in 2 ml total solution achieved 
the highest inhibition of crystal aggregation in the experiments performed by Hess et al. 
(1989). The percentage inhibition of both nucleation and aggregation by the test sample 
were determined from the following equations (Hess et al. 1995). 
% Nucleation inhibition (N1n) = [1 - T .rr ad x 100 %Aggregation inhibition (~n) = [1- T JT ad x 100 
T. = turbidity slope of plot of 001120 vs. time in the presence of test sample. 
T sc = turbidity slope of plot of 001120 vs. time of the control without test sample. 
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Preparation of calcium oxalate monohydrate (COM) crystals for growth assay 
COM crystals were prepared following the method of Pak et al. ( 1975). Equal volumes of 
10 mmol/L CaCh and 10 mmol/L Na20x solutions were mixed at a constant rate of 1 
ml/min using a peristaltic pump (Gilson, France). The mixture was then stirred at 4 OC for 
7 days. Thereafter, the crystals were filtered through 0.22 J!ID filter paper, washed with 
distilled water followed by methanol and then dried at 37 OC for one hour. 
Characterization of COM crystals 
The COM crystals were characterized using X-ray powder diffraction (XRD). Powdered 
crystals were packed into aluminium trays and X-ray diffraction patterns were recorded 
using a Phillips PW 1050/25 vertical goniometer with CuKa radiation of wavelength 
1.5418 A produced at 40 kV and 25 mA. The observed peaks were assigned by referring 
to the standard interplanar spacing and relative intensities for COM crystals (Sutor and 
Scheidt 1968) shown in Table 2.2. Relative intensities were compared qualitatively in the 
present study; quantitative measurements were not made. 
Table 2.2: Interplanar spacing and relative intensities of COM powder pattern. 
Standard d-spacing and relative Present study 
Intensity data for COM 
d-spacing ~) Relative intensity d-spacing (A) 





3.76 I 13 
3.65 100 3.67 
3.00 10 
2.97 46 2.98 
2.91 12 2.96 
2.89 10 
2.84 14 2.83 
2.51 2 
2.48 30 2.49 
2.41 5 
2.37 2 
2.34 90 2.33 
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Figure 2.4 shows the x-ray diffraction patterns obtained for COM crystals prepared using 
the method by Pak et al. (1975). Comparison with the standard x-ray diffraction data 












Figure 2.4: x-ray diffraction pattern obtained for COM crystals prepared 
using the method of Pak et al. (1975) 
Preparation of COM crystal slurry for growth assay 
A Tris buffer was prepared by mixing lOmM tris (hydroxymethyl)-aminomethane with 
90 mM NaCl and the solution was adjusted to pH 7.2 using 5M NaOH. The tris buffer 
was filtered (0.22 ~)before use. A seed crystal slurry was prepared by suspending the 
previously prepared COM crystals, in the same Tris buffer (16 mglml) and then allowing 
it to equilibrate overnight with fast stirring. 
CaOx crystal growth Assay 
The growth assay experiment was performed according to the method of Webber et al. 
(2007). A metastable solution of CaOx containing 0.5 mM CaCh and 0.5 mM Na20x was 
prepared in Tris buffer (which was described previously). 
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The solution was maintained at room temperature with fast stirring throughout the 
experimental period. If the solution turned cloudy, a fresh solution was prepared. After 
the seed crystal slurry was equilibrated overnight, a 2 ml aliquot of the metastable CaOx 
solution was transferred to a quartz cuvette which was placed in a spectrophotometer 
(Specord 40) and stirred at 500 rpm. Growth was induced by the addition of the 
previously prepared seed crystal slurry (50 f.d). Absorbance was monitored at 214 nm and 
3 7 oc for 30 minutes. Figure 2.5 shows a typical plot obtained for the crystal growth 
assay. 
0.95 
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Figure 2.5: A typical plot of absorbance vs. time for CaOx growth assay. 
The experiment was performed for (i) AU alone, (ii) real urine alone, (iii) AU + lime 
powder and (iv) real urine + lime powder. AU samples were tested at a ratio of 1600 J.d 
metastable solution of CaOx: 400 J!l urine (AU): 50 J!l COM slurry. On the other han~ 
for real urine samples, this ratio failed to produce detectable crystallization. Various ratios 
were tested. Finally a ratio of 1990 J!l metastable limit solution of CaOx: 10 Jil real urine 
and 50 J.d COM slurry was used to determine the growth of the crystals. Inhibition of 
growth (Ia) was calculated using the equation: 
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Inhibition growth (Io) = [ (Ac - AL) I Ac] X 100 
where, 
ll absorbance 
Ac=----- of the control 
ll time (400 sec) 
AL = ll absorbance 
of lime-dosed samples 
ll time (400 sec) 
2.2.5 BONN Risk Index (BRI) 
BRI is an experimentally determined ratio of the free ionized calcium concentration 
[Ca2i to the quantity of ammonium oxalate required to induce spontaneous 
crystallization of CaOx in the urine sample under investigation (Laube et al. 2004 ). BRI 
values < 1 denote that samples are not at risk for kidney stone disease while values > 1 
indicate that samples are at risk. 
Therefore, 
= free ionised calcium (mmol/1) 
quantity of ammonium oxalate required to induce crystallization 
(mmol/1 00 ml urine) 
BRI was determined in both the in vitro and in vivo (clinical trial) studies (Chapter 4 and 
5). 
2.2.6 Tiselius Risk Index (TRI) 
The Tiselius risk index expresses the biochemical risk of CaOx formation (Tiselius 1982). 
The mathematical expression is given by 
(Ca/Cr) 0·71 X (Ox/Cr) 
(Mg/Cr) 0·14 X (Cit/Cr) 0·10 
where Ca, Ox, Mg, and Cit are the urinary excretion (mmol per 24 hour) of calcium, 
oxalate, magnesium and citrate, respectively and Cr is the urinary excretion (mol per 24 
hour) of creatinine. TRI was determined in the clinical trial study only (Chapter 5). 
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2.2.7 Relative supersaturation (RS) 
The relative supersaturation values of CaOx (COM and COD), calcium phosphate 
(brushite) and uric acid were calculated by the computer program EQUIL 1.51 b using 
urine composition data (Ackermann et al. 1989; Brown et al. 1994). 
These relative supersaturations were determined in the clinical trial study (Chapter 5) 
only. 
2.2.8 Statistical analysis 
Mean values and standard errors ofthe means of all data were calculated using analysis of 
variance (SAS statistical package, Statistica 8). For all the data, on the reasonable 
assumption that the populations had the same variance, these variances were pooled and a 
single standard error was obtained. Results were considered statistically significant if p ~ 
0.05. 
Mean particle size distributions were also calculated. Skew-normal distributions were 
fitted to each mean data set using the software packageR (Azzalini and Dalla Valle 1999, 
2003) and the parameter values for the location, scale and shape were determined. These 
values were used to compute theoretical moments and particle modes. 
2.2.9 Ethics 
The project described in this dissertation was approved by the Ethics and Research 
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EFFECTS OF LIME POWDER 
SOLUTIONS ON CALCIUM OXALATE 




As stated in Chapter 1, citrus fruits/juices are a known natural source of dietary citrate. 
Citrate is a well known inhibitor of CaOx crystallization. The presence of citrate in urine 
decreases the saturation of CaOx and CaP by forming complexes with calcium. It also 
inhibits crystal nucleation, growth and aggregation (Ryall et al. 1981; Pak et al. 1985; Pak 
1987; Grases et al. 1989; Grases and Costa-Bauza 1990; Conte et al. 1990; Tiselius et al. 
1993; Laube et al. 2002). 
Lime is rich in citrate and therefore is expected to act as an inhibitor of CaOx 
crystallization. The investigation of lime is the focus of this dissertation. As a starting 
point, its potential inhibitory property towards CaOx crystallization in AU was tested. 
This chapter describes experiments which address aim (i) (page 27). 
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3.2 MATERIALS AND METHODS 
3.2.1 Study Design 
The lime powder was manufactured and prepared as described in Chapter 2.2.1 (page 50-
51). Solutions of different concentrations of lime powder were prepared using distilled 
water and were modelled on a study by Y achantha et al. 2007. The different 
concentrations of lime powder were 0.125, 0.250, 0.500 and 1.00 mg/ml. If the solutions 
turned cloudy, they were discarded and a new solution was prepared. The pH of the lime 
solutions were not measured 
3.2.2 Experimnltlll methods 
The AU used for this study was prepared as described in Chapter 2.2.2 (page 51). 
Crystllllit.olion experiments 
The CaOx metastable limi~ particle volume-size distribution, scanmng electron 
microscopy, crystal nucleation and aggregation inhibition, and CaOx crystal growth assay 
were determined in a control AU samples and in sample dosed with lime solutions of 
different concentrations. All these experiments were performed in duplicate. The 




3.3.1 Crystallization Experiments 
CaOxMSL 
Graphs of particle number versus sodium oxalate concentration for the determination of 
CaOx MSL values in the different experiments are presented in Figure 3.1. These show 
that the MSL did not change as a function of the concentration of the lime solution and 
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Figure 3.1: The CaOx MSL of AU before and after the addition of lime 





The mean PSDs of the control AU as well as those which had been dosed with lime 
solutions are presented in Figure 3.2. Quantitative values are given in Table 3.1. Plots of 
PSD experiments are given in Appendix 2. 
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Figure 3.2: Particle volume-size distributions of AU before and after the 
addition of lime solutions 
25 
Table 3.1: Data derived from particle size distribution of AU dosed with different 
solutions of lime powder 
Samples Particle size Particle volume 
mode(pm) peaks 
(xlfl Jl"l /500pl) 
AU control 7.18 34.4 
AU+ 0.125 mglml 7.70 104.6 
AU + 0.250 mglml 4.09 78.5 
AU+ 0.500 mg/ml 3.21 92.3 
AU +1.00 mglml 3.08 57.3 
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Statistical analysis of these distributions showed that particle size deer~ while the 
particle volwne increased as the concentration of the lime solution increased relative to 
the AU control. 
SEM 
Figures 3.3.1 and 3.3.2 show SEM micrographs of CaOx crystals precipitated from AU 
before and after the addition of lime solution respectively. Comparison shows that crystal 
number increased while crystal size decreased. It is also noted that the nature of the 
calciwn oxalate hydrate changed from only mono to a mixture of mono and dihydrate 
crystals (as indicated by red circle) after dosing with lime. 
Figure 3.3.1: AU control Figure 3.3.2: AU + 1.00 mglmllime 
Figure 3.3 Scanning electron micrographs of CaOx crystals deposited in AU before 
and after the addition ofthe highest concentration of lime solution (1.00 mg/ml). 
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CaOx crystal nucleation and aggregation 
The percentage inhibitions of both CaOx crystal nucleation and aggregation before and 
after the addition of different lime solutions are given in Table 3.2 and plots of 
absorbance vs time are shown in Figure 3.4. 
Table 3.2: The percentage inhibition (% In) of both CaOx crystal nucleation and 
aggregation in the absence and presence of lime solutions. 
Samples 
AU control 
AU + 0.125 mglml 
AU + 0.250 mglml 
AU + 0.500 mglml 
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Figure 3.4: Plot of absorbance vs time for the simultaneous nucleation 
and aggregation assay before and after the addition of lime solutions 
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The percentage inhibition of nucleation showed a general decrease with increasing 
concentrations of lime solutions. On the other han~ inhibition of CaOx crystal 
aggregation increased consistently with increasing concentration of lime solutions. The 
individual plots of these experiments are given in Appendix 3. 
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CaOx crystlll growth 
The effect of lime on the% inhibition of crystal growth in AU is shown in Figure 3.5. 
Inhibition increased steadily and consistently as the concentrations of lime increased. The 
individual plots of these experiments are given in Appendix 3. 
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Figure 3.5: Percentage inhibition of growth assay in the absence and the 




The results of the various crystallization experiments are summarised and briefly 
interpreted in Table 3.3. 
Table 3.3: A summary of results and interpretation showing the effect of lime 
concentrations (0.125 mg/m.l-1.00 mglml) in AU samples. 
Jlj • bl ana es 
I 
L nterpretatton: Effi ifl" ecto 1me 
MSL no change does not affect initiation 
of nucleation 
' 
l I PSD SIZe inhibits growth 
t I volume i promotes growth or nucleation 
SEM SIZe l inhibits growth 
number t promotes nucleation 
% Inhibition of l promotes nucleation 
crystal nucleation 
% Inhibition of t inhibits aggregation 
crystal aggregation 
i 







Since the CaOx MSL represents a measure of the ease or difficulty with which 
crystallization is initiated, the results of the present study have demonstrated that lime has 
no effect on this urinary property. However, once crystallization has commenced, the 
results show that lime does indeed have an effect on all three crystallization mechanisms. 
This conclusion can be drawn by consideration of the summary of results which are given 
in Table 3.3. It is observed that the total volume precipitated crystals in the PSDs, 
increased with increasing lime concentration. An increase in particle volume can arise as 
a result of an increase in crystal nucleation (more particles) or growth (bigger particles) or 
aggregation (in which the random packing of crystals creates pores which will ultimately 
increase the volume of the conglomerate). Promotion of growth can be ruled out by the 
results of the growth assay which demonstrated inhibition of this particular mechanism 
In addition, growth inhibition was also demonstrated by the SEM observations. Similarly, 
promotion of aggregation can also be discounted, as inhibition of this particular 
mechanism was demonstrated in the aggregation assay. 
Thus, promotion of nucleation remains the only possibility to account for the increase in 
particle volume. This is supported by the nucleation assay and by the SEM observation. 
Interestingly, nucleation has been interpreted as a favourable process as it provides a 
mechanism for rapidly decreasing saturation (Kavanagh 1992). 
Mixture of COM and COD crystals were deposited after the addition of lime solutions 
compared to only COM crystals in the control sample (Figure 3.3.1 ). These results are 
favourable and of great importance. This is due to the report by Wesson et al. (1998) that 
COD crystals are less adherent to renal tubular cells. The other reason for the importance 
of COD deposition is that the higher positive charge on these crystals results in greater 
repulsive forces between crystals and therefore favours disaggregation (Webber 2003). 
This is indeed supported by the % inhibition of CaOx aggregation which showed a 
consistent increase after the addition of lime solutions. 
It is noteworthy that the results which emerged in the present study in independent 




promotes nucleation (PSD, SEM, inhibition of nucleation assay), inhibits growth (PSD, 
SEM, inhibition of growth assay) and inhibits aggregation. 
Therefore, lime has been shown in the present study to have favourable effects in 
artificial urine on all three crystallization mechanisms and in the context of CaOx stone 
formation. 





o Conte A, Roca P, Gianotti M and Grases F (1990) On the relation between 
citrate and calcium in normal and stone-former subjects. lnt Urol Nephrol 
22:7. 
o Grases F, Genestar C, Conte A, March P and Costa-Bauza A (1989 ) 
Inhibitory effect of pyrophosphate, citrate, magnesium and chondroitin 
sulphate in calcium oxalate urolithiasis. Br J Uro164:235. 
o Grases F and Costa-Bauza A (1990) Study of factors affecting calcium oxalate 
crystalline aggregation. Br J Urol66:240. 
o Kavanagh JP (1992) Methods for the study of calcium oxalate crystallization 
and their application to urolithiasis research. Scanning Microsc 6: 685. 
o Laube N, Jansen B and Hesse A (2002) Citric acid or citrates in urine: which 
should we focus on in the prevention of calcium oxalate crystals and stones? 
Urol Res 30:336. 
o Pak CYC, Fuller C, Sakhaee K, Preminger GM and Britton F (1985) Long-
term treatment of calcium nephrolithiasis with potassium citrate. J Urol 
134:11. 
o Pak CYC (1987) Citrate and renal calculi. Mineral Electrolyte Metab 13:257. 
o Ryall RL, Harnett RM and Marshall VR (1981) The effect of urine, 
pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and 
aggregation of calcium oxalate crystals in vitro. C/in Chim Acta 112:349. 
o Tiselius H-G, Fomader AM and Nilsson MA (1993) The effects of citrate and 
urine on calcium oxalate crystal aggregation. Urol Res 21:363. 
o Webber D (2003) Urinary prothrombin fragment I: a potential role-player in 
the protection of South African blacks from calcium oxalate kidney stone 
disease. PhD thesis, University of Cape To~ South Africa. 
o Wesson JA, Worcester EM, Wiessner JH, Mandel NS and Kleinman JG 
(1998) Control of calcium oxalate crystal structure and cell adherence by 
urinary macromolecules. Kidney lnt 53:952. 
75 
Cfttpter Tftree 
o Yachantha C, Tosukhowong P, Sasivongsbhakdi T, Hossain~ Tungsanga K 
and Ogawa Y (2007) The effect of lime as natural source of potassium citrate 
on calcium oxalate crystallization, renal tubular cell injury and oxidative 
stress: in vitro and in human. In: Reis Santos JM and Rao N eds, Kidney 
Stones (Proceedings of the 5Th eULIS Symposium on Urolithiasis). Editoriale 
Bios, Lisbon/Cascais, Portugal. 
76 
CHAPTER FOUR 
IN VITRO EFFECTS OF LIME 
POWDER SOLUTIONS ON CALCIUM 




In the previous section, the simple model of an artificial urine was used as the solution 
medium. Real urine is far more complex. Extension of the investigation to this medium is 
essential in order to establish the effects of lime solutions in humans. 
Previous studies on the in vitro effects of fruit juices and natural extracts include that of 
Atmani and Khan (2000), Yachantba et al. (2007) and Kulaksizoglu et al. (2008). These 
have shown that the citrus fruits are capable of inhibiting CaOx crystallization. 
OBJECTIVES 
The objective of this study was to investigate the effect of lime powder on CaOx 
crystallization in urine obtained from South African black and white subjects with a view 
to exploring whether: 
(i) similar results would be obtained to those obtained in AU 
(ii) different results might be obtained in the urine from the two race groups. 
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4.2 MATERIALS AND METHODS 
4.2.1 Stlllly design 
Two groups, consisting of 5 healthy South African black males and 5 healthy South 
African white males respectively, were age matched (ages 18-32). They were recruited 
from the undergraduate and postgraduate cohorts at University of Cape Town. None of 
the subjects in either group had a metabolic illness or any clinical problem and had no 
history of kidney stones. 
For each subject, brief information about their social and medical history was collected as 
shown in Table 4.1. Details of the questionnaire are given in Appendix 4. 
Table 4.1: Examples of the information requested about the subjects' social and 
medical history. 
lnfot71U11ion Requested Ex.mples 
General Name of subject, date of birth & date 
of participation in project 
Nutritional/Exercise Weight, height, allergic food, special 
diets, supplements, exercise 
Exposure to toxic substances Number of daily alcohol drinks 
Medical history Recent illness, current medication 
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The purpose and procedure of the study was explained to each subject and those who 
agreed to participate in the study signed a letter of consent (Appendix 4). 
During the urine collection day (described on page 80), subjects were on a free diet but 
were advised to avoid certain foods according to Table 4.2 and to increase their fluid 
intake. Thus, subjects served as their own controls in accordance with the study by 
K.arag{Ule et al. (2007). A 24-hour dietary recall questionnaire was used to record food 
and drinks on the day of urine collection. Food and drinks were analysed for macro- and 
micronutrients using the computer programme "Foodfmder" version 2 (Wolmarans et al. 
_001). 
Table 4.2: Examples of food that subjects were advised to avoid on the day of urine 
collection. 
r,..,,.. &.nples 
Oxalate-rich food Spinach, rhubarb, beetroot, peanuts, 
cocoa, chocolate, tea, coffee 
Salty food Processed meats, snack foods, stock 
cubes, salty condiments and sauces, 
packed and tinned soups 
Calcium-rich food Fat-free milk, cheese, yoghurt 
Different concentrations of lime solutions were prepared usmg distilled water as 
explained in Chapter 3.2. The concentrations which were used for this study were 0.125, 
0.500 and 1.00 mg/ml. These concentrations were modelled from the ones used in the 
study by Yachantha et al. (2007). However, three out of four concentrations were used in 
this study as opposed to the AU study, due to experimental constraints. 
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4.2.2 Experimelltlll mdhods 
Urine coUection 
24 hour urine samples were collected in plastic bottles without preservative from each of 
the participants as explained in Chapter 2 (page 52). 
CrystlllliZillion experiments 
The CaOx MS~ PSD, crystal nucleation and aggregation inhibition, and CaOx crystal 
growth assay were determined in control samples of all subjects (blacks and whites) and 
in samples dosed with lime solutions of different concentrations. The techniques have 
been described in Chapter 2. 
Free calcium ion concentrations and BRI 
These parameters were determined as described in Chapter 2.2.5 (page 60). 2500 JLl of 
lime solutions ranging from 0.125 to 1.00 mglml was added to 100 ml of each urine 
sample under investigation. Measurements were taken before and after dosing the urines 
with lime. 
Stlltisticalanalysis 




4.3.1 Soda/ {llfd medical history 
Ten South African males participated in the study and were aged between 18-32 as 
mentioned on page 78. The study was conducted over 8 weeks. It was found that blacks 
had identical body mass index (BMI) to that of whites (23.03 vs 22.80) as shown in Table 
4.3. On the other band, white subjects participated in different physical exercises and they 
were exposed to alcohols (2-3 glasses) daily, while some black subjects were not involved 
in any exercises and most of them did not drink alcohol. None of the subjects were on 
special diet, had any illness and hence were not taking any medication prior the study. 
4.3.2 Dkttuy 111111lysis 
The mean intake of nutrients on the day of urine collection for the two race groups was 
determined from the completed dietary recall questionnaires. Values are given in Table 
4.3. It is noted that only calcium was significantly different between the groups, namely 
the intake was lower in black subjects (340.4 mglday vs 631.1 mglday, p = 0.031). This is 




Table 4.3: Mean daily intake of nutrients for black and white subjects (SE) 
Variables Blacks Whites P-values 
Moisture 2965.9 (536.5) 2053 (536.5) 0.263 
Total 69.82 (9.46) 68.16 (9.46) 0.904 
Protein (g/day) 
Animal 43.86 (7.39) 32.14 (7.39) 0.295 
Protein (glday) 
Total fat (glday) 42.68 (9.64) 47.82 (9.64) 0.716 
Carbohydrate (glday) 185.48 (35.36) 163.74 (35.36) 0.675 
Fibre (glday) 18.78 (4.64) 24.12 (4.64 0.439 
Added sugar (g/day) 26.12 (4.45) 19.18 (4.45) 0.302 
Oxalate (mglday) 42.80 (23.68) 34.40 (23.68) 0.808 
Ca(mg/day) 340.40 (82.41) 631.60 (82.41) 0.037* 
Mg(mglday) 243.40 (45.83) 289.60 (45.83) 0.496 
Phosphate (mglday) 950.40 (145.7) 1305.0 (145.7) 0.123 
K(mglday) 1570.40 (423.5) 2157.20 (423.5) 0.355 
Na(mg/day) 1634.80 (219.9) 1842.40 (219.9) 0.523 
Vitamin A (RFJday) 2912.00 (183.3) 6116.00 (183.3) 0.251 
Vitamin 86(mg/day) 1.33 (0.381) 1.57 (0.381) 0.662 
Vitamin C (mg/day) 76.60 (25.12) 65.00 (25.12) 0.836 
Vitamin D (Jig/day) 2.166 (0.829) 2.746 (0.829) 0.634 
BMI 23.04 (1.174) 22.80 (1.174 0.889 
. 
*Stgnificance at p<0.05 
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Figure 4.1: Comparison of the means of calcium intake for black and white subjects 
4.3.3 CrysltlllivltJon Experiments 
CaOxMSL 
Figure 4.2 gives mean plots for the detennination of the CaOx MSL in the control urines 
of 5 black subjects and 5 white subjects. These graphs show that the MSL in the urine of 
black subjects is higher than that in white subjects i.e. of 75 vs 45 JJ.moVl respectively. 
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Within each group the CaOx MSL did not change after addition of lime solutions. This is 
demonstrated for black subjects in Figure 4.3. 
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Figure 4.3: The CaOx MSL of black subjects' before and after the addition 




Mean PSD plots for black and white subjects are shown in Figure 4.4 (I) and Figure 4.4 
(2) respectively. Quantitative values for the mean particle sizes and particle volumes are 
given in Table 4.4. It is noted that mean sizes tended to decrease with increasing lime 
concentrations, albeit that there was a single outlier in both groups. Particle volumes of 
black subjects did not change with increasing concentrations of lime powder (except for 
the one outlier) while particle volumes of white subjects decreased with increasing lime 
concentrations. PSD plots for each subject are given in Appendix 2. 
Figure 4.4.1 
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Figure 4.4: Mean PSD of black subjects (4.5.1) and white subjects (4.52) before 








Table 4.4: Data derived from PSD of urines of black and white subjects before and after 
the addition of lime solutions. 
Santpla Particle siu · Particle voiiiiPie 
motk(Jun) ·peaks 
1 (xl II pm' 1500pl) 
BU control 6.17 196.51 
BU + 0.125 mglml 5.77 160.26 
BU + 0.500 mglml 6.76 196.66 
BU + 1.00 mglml 5.64 196.51 
WU control 8.05 105.60 
WU + 0.125 mglml 8.85 81.41 
WU + 0.500 mglml 6.97 58.76 
WU + 1.00 mglml 7.21 48.24 
SEM 
Figure 4.5 shows the SEM micrographs of CaOx crystals precipitated from the urine of 
black and white subjects before and after addition of lime solutions. The crystals were all 
viewed at 4000X magnification. Figures 4.5.1-4.5.4 represent the deposited crystals of 
black subjects while Figures 4.5.5-4.5.8 represent those of the white subjects. 
Crystal numbers increased with increasing lime concentrations in black subjects while 
decreased in white subjects. On the other hand, CaOx crystal sizes tended to remain 
unchanged in black subjects but appeared to be bigger in white subjects after the addition 
of lime solutions, relative to the control. The number of aggregated crystals in the urines 
of white subjects decreased with increasing lime concentrations whereas aggregated 
crystals were not observed in black subjects. A mixture of COM and COD crystals were 
observed in the control samples of black subjects, but COM crystals were precipitated as 
lime was added. On the other hand, COD crystals were observed in white subjects before 
and after the addition of lime concentrations. 
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Figure 4.5.1: Figure 4.5.2: Figure 4.5.3: Figure 4.5.4: 
BU control BU + 0.125 mg/ml BU + 0.500 mg/ml BU + 1.00 mg/ml 
Figure 4.5.5: Figure 4.5.6: Figure 4.5. 7: Figure 4.5.8: 
WU control WU + 0.125 mg/ml WU + 0.500 mg/ml WU + 1.00 mg/ml 
Figure 4.5: Scanning electron micrographs of CaOx crystals deposited in the 
urines black and white subjects before and after the addition of lime solutions 
CaOx crystal nucleation and aggregation 
Table 4.5 shows that the mean % of inhibition of CaOx nucleation showed a general 
tendency to decrease in both groups thereby indicating a tendency towards promotion of 
nucleation. It is also noted that the values for white subjects were generally higher, 
thereby suggesting that promotion of nucleation is greater in the black group. 
The mean % inhibition of CaOx aggregation in the urine of black subjects increased 
consistently as the lime concentrations increased, achieving statistical significance at the 
two highest concentrations. On the other hand, no obvious trend was apparent in the urine 





Table 4.5: Mean percentage inhibition (% In) of CaOx crystal nucleation and 
aggregation as a function of lime concentrations in the urine of black and white 
subjects (SE) 
Samples " I If of Nucleatiolf P-valua " llf Df Aggregatiolf P-values 
BU 67.2 (7 .258) 62.6 (9.197) 
BU + 0.125 mglml 60.4 (9 .448) 0.345 69.8 (10.23) 0.323 
BU + 0.500 mglml 55.2 (9.851) 0.108 77.6 (9.271) 0.045• 
BU + 1.00 mglml 57.8 (7.319) 0.200 81.3 (7 .348) 0.014• 
wu 82.9 (7 .258) 77.9 (9.197) 
WU + 0.125 mglml 60.2 (9.448) o.oo5• 69.8 (10.23) 0.260 
WU + 0.500 mglml 70.4 (9.851) 0.100 72.0 (9.271) 0.413 
WU + 1.00 mglml 73.9 (7.319) 0.231 82.4 (7.348) 0.533 
•significance at p<0.05 
CaOx crystlll growth 
Table 4.6 shows the mean % inhibition of CaOx growth in both groups. It is noted that 
there is a general tendency for this property to increase in both groups with increasing 
lime concentrations. Plots of each subject of these experiments are shown in Appendix 3. 
Table 4.6: Mean percentage inhibition (% In) of CaOx crystal growth as a function of 
lime concentrations in the urine of black and white subjects (SE) 
Samples " I If of Growth P-values 
BU -7.0 (5.06) 
BU + 0.125 mglml 1.4(6.17) 0.208 
BU + 0.500 mglml 3.5 (7.17) o.oo5• 
BU + 1.00 mglml 2.1 (5.89) 0.176 
wu -11.2 (5.06) 
WU + 0.125 mglml -6.9 (6.17) 0.516 
WU + 0.500 mglml -l.S (7.17) 0.152 
WU + 1.00 mglml 5.1 (5.89) 0.016• 
*Stgmficance at p<O.OS 
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Free cakium (lf) tllld BRJ 
Mean free Ca2+ concentrations and BRI values for both groups are given in Table 4.7. It is 
noted that mean free Ca2+ in black subjects showed no difference after dosing with 
different lime solutions, while for white subjects a significant decrease occurred after 
dosing with 1.00 mg/ml concentration. Mean BRI values for both groups decreased with 
increasing concentrations of lime powder. It is also noted that black subjects have lower 
BRI values than their white counterparts. 
Table 4. 7: The mean percentage of free Ca2+ concentration and BRI values in the 
absence and presence of lime solutions for black and white subjects (SE) 
Slllllples FreeOI"' P·values BRJ P·val~~n 
BU 0.306 (0.072) 0.826 (0.417) 
BU + 0.125 mg/m1 0.303 (0.061) 0.883 0.951 (0.346) 0.639 
BU + 0.500 mglml 0.298 (0.054) 0.644 0.874 (0.361) 0.855 
BU + 1.00 mglml 0.298 (0.050) 0.644 0.814 (0.336) 0.965 
wu 0.444 (0.072) 1.940 (0.414) 
WU + 0.125 mglml 0.430 (0.061) 0.421 1.876 (0.346) 0.809 
WU + 0.500 mglm1 0.417 (0.054) 0.129 1.844 (0.361) 0.719 
WU + 1.00 mglml OAOt (0.050) 0.017• 1. 740 (0.336) 0.451 




The results of various crystallization experiments are summarised and briefly interpreted 
in Table 4.8. 
Table 4.8: A summary of results and interpretation showing the effect of lime 
concentrations (0.125 mg/ml-1.00 mglml) in samples from black and white subjects 
' 
Variables Blacks I Whites lntef1J.reJation: Effect of lime 
' 
I 
MSL no change no change does not affect initiation of 
nucleation in each group 
PSD size ~ ~ inhibits growth in both groups 
' 
I 
volume no change ~ inhibits growth or nucleation 
I 
or aggregation in whites 
SEM Size no change t promotes growth in whites 
number t ~ promotes nucleation in blacks, inhibits nucleation in whites 
-
% inhibition of ~ ~ promotes nucleation in both crystal nucleation ' groups 
% inhibition of t i t inhibits aggregation in both 
crystal awegation groups 
% inhibition of t t inhibits growth in both groups 
crystal growth I 
I I 
Free Ca2+ ~ ~ binds Ca2+ in both groups 
i 
' 




Interesting results have been observed in the urine from both groups in this study. CaOx 
MSL was demonstrated to be higher in black subjects indicating that induction of 
crystallization is less easily achieved in this group. This is commensurate with the rarity 
of stones in blacks. 
Lime did not affect the MSL in either group. This is not unusual as other inhibitory 
substances such as citrate (Ryall et al 1985), urinary glycosaminoglycans (GAGs) e.g. 
heparin sulphate (Suzuki and Ryall 1996),. and proteins e.g. Tamm-Horsfall mucoprotein 
and phrothrombin fragment 1 (Grover et al. 1994; Grover and Ryall 2002) have also been 
reported as having no effect on CaOx metastable limit. 
Table 4.8 shows that lime induced the same effects in both groups except in the PSD 
(volume) determinations and in the SEM investigations. Regarding the effects common to 
both groups, it is noted that lime promoted CaOx crystal nucleation (nucleation assay), 
inhibited growth (growth assay) and inhibited aggregation (aggregation assay). 
Robertson and Scurr ( 1986) noticed that citrate was able to promote nucleation. The 
present results show that the addition of lime solutions to the urine of both groups 
promoted nucleation of CaOx crystals. The authors also showed that citrate was able to 
reduce the crystal growth. Hennequin et al. (1993) with another model of crystallization 
confinned that citrate showed 50 % inhibition of crystal growth. 
Kok et al. (1986, 1988) in their studies about citrate on in vitro crystallization model, 
showed that citrate had a strong activity against crystal aggregation. Another in vitro 
study by Kulaksizoglu et al. (2007) on lemon and orange juices showed that lemon which 
is also rich in citrate was found to inhibit the rate of crystal aggregation. On that note, the 
present results showed that lime had also the capability of inhibiting CaOx crystal growth 
and aggregation for both population groups as seen in Table 4.8. This is promising and 
supports what has already been reported in the literature. 
These are all very favourable outcomes in the context of urolithiasis as each represents a 
reduced risk of stone formation. The PSD (size) results support the aforementioned 
conclusion that lime inhibits CaOx crystal growth in the urine of both groups. In addition 
pH was not affected by lime solutions. However, this is in conflict with the SEM results 
which suggest that growth is promoted in whites. 
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Since inhibition of growth is also indicated by the PSD (volume) results in whites, it is 
likely that this protective mechanism is indeed occurring. 
The only other result which contradicts the assay interpretations is the SEM (number) 
observation of a decrease in whites which suggest inhibition of nucleation. Since the 
assay and the SEM studies must be regarded as being of equal credibility, it is not 
possible to draw a firm conclusion about the effect of lime on nucleation in the urine of 
whites. However, despite this uncertainty, the two remaining variables, (free Ca2+ and 
BRI) both demonstrate empirically that lime lowers the risk of CaOx crystallization in the 
urines of black and white subjects. 
Another distinction between the urinary responses in black and white subjects is that the 
former precipitated COM crystals while the latter precipitated COD crystals. The 
suggested reason for the COD precipitated crystals in white subjects is that they have 
higher urinary calcium concentrations which as a result favour the formation of these 
crystals (Webber et al. 2002). Although urinary calcium was not measured in this study, 
the high intake of calcium in this group as shown in Table 4.3 might suggest that their 
urinary calcium was also high as compared to blacks. The formation of COD crystals is of 
great importance because they show a lower binding affinity for epithelial cell surfaces 
than COM crystals, thus inhibiting the critical step in the formation of kidney stones 
(Wesson et al. 1998). These results showed that there is a difference between the two 
South African population groups which confinns what has already been reported in the 
literature. They also show that similar results to that obtained in the AU study were also 
observed in this study, once again suggesting that lime has favourable effects in the 
context of CaOx stone formation 
When combined with the favourable reduction in the other risk factors described above, a 
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CHAPTER .FIVE 
CLINICAL TRIAL TO INVESTIGATE 
THE EFFECT OF THE INGESTION OF 
LIME POWDER SOLUTION ON 
CALCIUM OXALATE 
CRYSTALLIZATION IN REAL URINE 
Ch'9'ter Five 
5.1/NTRODUCTION 
Citrate is an important inhibitory substance as it forms soluble complexes with calcium in 
urine. It reduces the saturation ofCaOx and CaP and inhibits crystallization (Pak 1987). 
As mentioned in Chapter 1, citrus fruits and juices (lemon, orange, grapefruits, and lime) 
are a dietary source of citrate and therefore could represent an alternative to 
pharmacological citrate therapy. 
Several studies have investigated the impact of citrus juices on urinary parameters in 
kidney stone patients and some in healthy subjects. Wabner and Pak (1993) showed that 
orange juice caused an increase in urinary citrate and oxalate levels while it decreased 
calcium excretion. More studies on lemon juice (Seltzer et al. 1996; Kang et al. 2007; 
Penniston et al. 2007; Aras et al. 2008) showed an increased urinary citrate excretion. 
They also showed increased urinary pH and decreased calcium levels after the ingestion 
of lemon juice. Goldfarb and Asplin (200 1) reported that citrate and oxalate levels were 
increased in healthy subjects after the intake of grapefruit juice for 7 days. The effect of 
lime juice on urinary pH investigated by Mazdak et al. (2006) in healthy subjects showed 
that the juice increased the urinary pH, while in another study by Tosukhowong et al. 
(2008) on nephrolithiasis patients, lime increased urinary citrate, pH and potassium. 
Having established that solutions of lime favourably alter the urinary risk factors for 
CaOx stone formation in vitro, it makes sound scientific sense to investigate its effect in 
vivo. This section focuses on whether lime powder could be a therapeutic agent for 
nephrolithiasis as suggested by the previously described in vitro studies and also 




5.1 MATERIALS AND METHODS 
5.2.1 Study dnlgn 
5 black and 5 white age-matched South African males (ages 20-28 years), were recruited 
from the undergraduate and postgraduate cohorts of the University of Cape Town. 
However, one of the 5 white subjects was subsequently excluded because of his 
extremely high urinary creatinine value. None of the subjects in either group had 
metabolic illness or any clinical problems. They were instructed to stop taking any 
supplements three days before commencement of the study. None of the subjects had a 
history of kidney stones. 
For each subject, brief information about their social and medical history was collected as 
explained in Chapter 4.2 and an instruction sheet on how to collect the 24-hour urine and 
to take lime powder, was provided (Appendix 4). Those who agreed to participate in the 
study after a verbal and written explanation were given a letter of consent to sign 
(Appendix 4). 
Each subject was asked to collect a 24-hour baseline urine before the ingestion of lime 
powder. They were given seven sachets of lime powder (5g each) to drink with warm 
water every day. On the th day, subjects were again asked to collect a 24-hour urine. 
As with the in vitro study, subjects were on a free diet but were advised to avoid certain 
foods (fable 4.2). They were instructed to control their diet by eating the same food on 
the baseline day and on day 7, as implemented by KaragO.lle et al. (2007). A 24-hour 
dietary recall questionnaire was used to record food and drinks ingested at baseline and 
on day 7 as explained in Chapter 4.2. 
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5.2.2 Experlmelltlll methods 
Urine coUectlon and analysis 
24-hour urine samples were collected in plastic bottles without preservative from the 
recruited subjects at baseline and on day 7. Each sample was tested for haematuria and 
nitrite using urinalysis test strips and those that tested positive for either were discarded. 
All urine samples were analysed for pH, sodium, potassium, calcium, oxalate, urate, 
citrate, chloride, magnesium, phosphate and creatinine as described in Chapter 2.2.3 
(page 52). 
CrySIIlllluztlon experi~Mnts 
The CaOx MSL, PSD, crystal nucleation and aggregation inhibition, and CaOx crystal 
growth assay were determined in the baseline samples and in samples after the ingestion 
of lime powder. The techniques have been described in Chapter 2. 
Free cllld111r1 ion concentratioiiS tnrd BRI 
These parameters were determined as described in Chapter 2.2.5 (page 60). 100 ml of 
each urine sample collected before and after the ingestion of lime powder was used to 
measure free calcium (Cr) and BRI. 
Statistkllllllltllysls 




5.3.1 Social tutd medkal history 
As in the in vitro study, it was found that black subjects bad higher weight hence high 
BMI as shown in Table 5.1 . 1bey were not on any specific diet and most of them were 
not exercising but were exposed to alcohol. On the other hand, two white subjects were 
on supplements (but were asked to stop taking them 3 days before the commencement of 
the study as explained in Chapter 2.2 on page 52). White subjects were exposed to 
alcohol and they were engaged in different kinds of exercises. None of the subjects bad 
experienced recent illness or were taking any medication prior the study. 
5.3.2 DlettUy lllllllpls 
The mean intake of nutrients for the two groups was determined from the completed 
dietary questionnaires. The values are given in Table 5.1. Because the subjects were 
asked to ingest the same food on both days, the average intake of nutrients was used for 
this study. Subjects who were non compliant with their diet were eliminated from the 
study. This was observed from the 24-hour dietary recall questionnaire which was used to 
record food and drinks ingested. Total protein and animal protein were the only nutrients 
which were significantly different between the groups; conswnption in both cases being 
higher for the black subjects. The mean with standard error of both total protein and 
animal protein is illustrated graphically in Figure 5.1. The daily nutrient intake of each 




Table 5.1: Mean daily intake of nutrients for black and white subjects 
Variables Blllclcs (11 =5) Whites (11 =4) 
Moisture 1104 (304.3) 1413 (304.3) 
Total Protein Uifday) 110.2 (13.46) 54.16 (13.46) 
Animal Protein (g/day) 66.28 (83S2) 29.00 {1.352) 
Total fat {&/_day) 60.52 {_12.25) 48.04 (12.251 
Carbohydrate (g/day) 280.8 (44.80) 216.3 (44.80) 
Fibre (g/day) 33.78 (6.074) 18.00 (6.074) 
Added sugar Uifday) 58.44 (17 .30) 58.70 (17.30) 
Oxalate (mg/day) 18.40 (12.76) 49.60 (12.76) 
Ca(mglday) 529.0 (106.8) 555.0 (106.8) 
Mg(mg/day) 339.0 (64.49) 254.0 (64.49) 
Phosphate (mg/day) 1320 (178.6) 897 (178.6) 
K(mg/day) 2786 (410.5) 2113 (410.5) 
Na(mglday) 2196 (347.7} 1366 {347.7) 
Vitamin A (RE/day) 679.0 _(_271.3) 1048 (271.3) 
Vitamin B6 {mg/day) 2.214 {0.343) 2.000 (0.343) 
Vitamin C (mg/day) 193.6 (67.24) 40.23 (67.24) 
Vitamin D (ltglday) 4.428 ( 1.268) 2.955 (1.268) 
BMI 28.42 (2.266} 24.7 (2.266) 
*Stgmficance at p<O.OS 
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Figure 5.1: Comparison of the means of total protein and animal 



































5.3.3 Urine compositio11 
Urinary parameters and computed risk indices for both race groups prior the 
administration of lime powder are given in Table 5.2. It is noted that the urinary 
magnesium is significantly lower in blacks (1.80 vs 3.86 mmol/24h, p =- 0.001) and also 
the Tiselius risk index (TRI) (computed from urinary calcium, magnesium, citrate, 
oxalate and creatinine) is significantly lower in this group compared to whites (203 vs 
304, p = 0.0102). 
Comparison of parameters before and after the ingestion of lime powder within each 
group is also shown in the same table (Table 5.2). The table shows that the only urinary 
variables which changed significantly were magnesium and phosphate excretions which 
increased in black subjects (1.80 vs 2.75 mmol/24h, p = 0.0001 and 20.9 vs 24.6 
mmol/24h, p = 0.023 respectively). On the other hand, a decrease in urinary oxalate after 
7 days of lime powder ingestion (0.313 vs 0.205 mmol/24h, p = 0.023) was observed in 
whites. TRI was also decreased significantly in this group (304 vs 187, p = 0.019). The 
urine composition and computed risk indices of each subject are given in Appendix 6. 
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Table 5.2: Comparison of mean winary parameters (SE) before and after the 
ingestion of lime powder in both race groups 
Blacks (n=5) Whites (n=4) 
Varillbles Baseline Day7 Pvalues Baseline Day7 P-
values 
pH 6.28 6.04 0.223 5.71 6.02 0.346 
(0.116) (0.116) (0.071) (0.071) 
Volume 1475 1878 0.257 1805 1500 0.438 
(mU24h) (215.6) (215.6) (89.3) (89.3) 
Citrate 2.04 2.96 0.125 2.64 5.56 0.0894 
(mmoV24h) (0.338) (0.338) (0.786) (0.786) 
Oxalate 0.222 0.294 0.294 0.313 0.205 0.023* 
(mmoV24h) (0.042) (0.042) (0.0306) (0.()306) 
Calcium 2.82 2.98 0.114 4.44 4.04 0.736 
(mmoV24h) (0.055) (0.055) (0.271) (0.271) 
Magnesium 1.80 2.75 o.ooo1• 3.86 4.16 0.598 
(mmoV24h) .(OJJ55) (O.OSS) (0.186) (0.186) 
Sodium 149 144 0.913 126 129 0.867 
(mmoV24h) (26.2) (26.2) (7.07) (7.07) 
Potassium 50.9 67.0 0.157 57.6 72.6 0.249 
(mmoV24h) (6.53) (6.53) (7.19) (7.17) 
Urate 2.98 3.36 0.347 2.88 3.38 0.663 
(mmoV24h) (0.252) (0.252) (0.423) (0.423) 
Creatinine 142 14.7 0.663 15.5 16.4 0.836 
(moV24h) (0.782) (0.782) (2.31) (2.31) 
Phosphate 20.9 24.6 0.023* 26.2 29.8 0.619 
(mmoV24h) (0.714) (0.714) (3.77) (3.77) 
Chloride 145 153 0.880 133 143 0.801 
(mmoV24h) (34.4) (34.4) (25.9) (25.9) 
RSCOM 6.66 7.24 0.199 7.61 7.26 0.374 
(0.269) (0.269) (0.0792) (0.0792) 
RSCOD 2.65 3.08 0.088 3.24 3.09 0.381 
(0.136) (0.136) (0.0336) (0.0336) 
RS Brushite 3.81E-09 3.81E-09 0.979 2.66E-09 2.08E-09 0.679 
{0.00} (0.00) (0.00) {O.OOJ 
RS Uric Acid 3.62 4.82 0.296 5.93 4.99 0.517 
(0.704) (0.704) (0.284) (0.284) 
Tiselius risk 203 243 0.346 304 187 0.019* 
index (26.9} (26.9} (29.4) (29.4) 
























Results of the crystaiJization parameters are shown in Table 5.3. It is apparent that there 
were no statistically significant differences between the groups for any of the 
crystalJization parameters at baseline. However, it is noted that free Ca2+ and BRI values 
tend to be lower in blacks while MSL values tend to be higher. 
On the other hand, the same table shows a comparison of the crystalJization variables 
before and after ingestion of lime powder. A significant increase of the inhibition of 
CaOx crystal aggregation in black subjects was observed after day 7 (72.9 vs 78.1, 
p = 0.031 ). No other significant differences occurred, although there was an increase in 
the MSL for whites which is approaching significance. The MSL data and plots of each 
urine sample are shown in Appendix 1 while the plots for nucleation, aggregation and 
growth assays for each subject are shown in Appendix 3. 
Table 5.3: Comparison of mean variables (SE) before and after the ingestion of lime 
powder in both race groups 
Blacks (11=5) Whites (11=4) Blacksvs 
Whites 
Variables Baseline Day1 Pvalun Baselbte Day1 P- Baseline 
valiii!S P-valws 
%In of 68.9 70.7 0.607 71.9 67.6 0.526 0.794 
Nucleation (2.30) (2.30) (4.35) (4.35) 
%In of 72.9 78.1 0.031* 71.1 69.1 0.844 0.763 
Aggregation (1.07) (1.07) (6.49) (6.49) 
% In of Growth 28.1 -2.572) 0.171 0.635 10.05 0.381 0.463 
(0.130) (0.130) (0.793) (0.793) 
Free Ca.l+ 0.181 0.290 0.280 0.684 0.415 0.229 0.176 
(0.062) (0.062) (0.126) (0.126) 
BRI 0.592 0.563 0.921 2.75 1.00 0.228 0.213 
(0.189) (0.189) (0.820) (0.820) 
MSL (mmolll) 78.0 87.00 0.591 48.7 82.5 0.057 0.282 
(10.9) (10.9) (7.95) (7.95) 




The PSD of both groups are illustrated in Figure 5.2. The graphs show that the particle 
sizes for both groups did not change statistically (4.32 vs 5.54 J.lm for blacks; p = 0.494 
and 6.014 vs 6.912 J.lm for white; p = 0.959). Particle volumes for black subjects did not 
change (88.8 vs 91.3 X 1ol J,lm3/500 J.ll) while for white subjects, the particle volume 
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Figure 5.2: Mean PSD ofblack subjects (5.2.1) and white subjects (5.2.2) before 
and after the ingestion of lime powder. 
SEM 
Figure 5.3 shows scanning electron micrographs of crystals deposited after the induction 
of CaOx crystallization in mines from both black and white subjects. The crystals were 
all viewed at 4000X magnification. 
Figure 5.3.1 shows that only COM crystals were deposited at baseline in blacks while 
Figure 5.3.2 shows that crystal numbers decreased after 7 days of ingesting the lime 
powder. 
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On the other band, Figure 5.3.3 represents the micrographs of urine crystals from white 
subjects at baseline. 1bis shows relatively large COD crystals, some of which are 
aggregated (circled in red), whereas Figure 5.3.4 shows that fewer COD crystals of 
smaller sizes were precipitated after 7 days of lime ingestion. No aggregated crystals were 
observed as compared to the baseline micrograph. 
Figure 5.3.1 Figure 5.3.2 
Figure 5.3: Scanning electron micrographs of CaOx crystals induced from the 
urine of black subjects before (baseline) and after the ingestion of lime powder 
(day 7) 
Figure 5.3 .3 Figure 5.3.4 
Figure 5.3: Scanning electron micrographs of CaOx crystals induced from the 
urine of white subjects before (baseline) and after the ingestion of lime powder 






The results of various urine composition and crystallization experiments are summarised 
and briefly interpreted in Table 5.4. 
Table 5.4: Summary of the urine composition and crystallization results after the 
ingestion of lime powder for 7 days. 
Variables Blacks Whites Interpretation: Effect of lime 
I 
Urinary risk factors magnesium f oxalate l reduces the risk in whites 
t l 
promotes risk in blacks due to 
phosphate TRI increased urinary phosphate 
' 
' 
MSL no change 
I 
no change no effect on initiation of 
nucleation 
PSD size no change no change 
volume t ' promotes nucleation, growth no change ' or aggregation in whites 
SEM size no change l inhibits growth in whites 
nwnber l l inhibits nucleation in both 
l 
groups 
aggregation no change inhibits aggregation in whites 
% Inhibition of t l inhibits nucleation in blacks crystal nucleation promotes nucleation in whites 
% Inhibition of t l inhibits aggregation in blacks crystal aggregation promotes aggregation in whites 
I 
% Inhibition of l t promotes growth in blacks 
crystal growth I inhibits growth in whites 
Free ;+ t l binds Cal+ in whites and not in 
blacks 




Table 5.4 shows the summary of the effect of lime powder in black and white groups. The 
table shows that lime powder acted favourably on two urinary parameters in white 
subjects. Oxalate is a urinary parameter which is regarded as being a highly important 
factor in CaOx kidney stones formation (Borsatti 1991 ). Because there is much less 
oxalate than calcium in the urine, it means that small increases in oxalate concentration 
has a far greater impact than changes in calcium concentration. Thus, the decrease in 
urinary oxalate in the white subjects after the ingestion of lime powder is of great 
importance. In the previous study by Tosukhowong et al. (2008) involving urolithiasis 
patients (wherein patients were given lime powder) for a period of3 months, they did not 
show a significant decrease in oxalate excretion. 
The TRI in the present study also decreased favourably in this group after the ingestion of 
lime powder. 
Crystallization experiments indicate that lime promotes nucleation (PSD vo4 nucleation 
assay) in whites. However, this is contradicted by SEM observations which suggest 
inhibition of this process. 'This is inconclusive. However, there is a strong empirical 
evidence to suggest that lime inhibits CaOx growth in this group (SEM, growth assay). 
Aggregation is promoted (PSD vol, aggregation assay). 'This is however contradicted by 
SEM. Therefore the results in whites are inconclusive with respect to nucleation and 
aggregation, but supportive of growth inhibition. Also, very importantly, free Ca2+ and 
BRI decreased (both are influential risk factors). Therefore the overall conclusion is that 
lime had favourable effects for reducing the risk of CaOx kidney stones in this group. 
In black subjects, a favourable increase of urinary magnesium was accompanied by an 
unfavourable increase in urinary phosphate (which is a risk factor for CaP stones) after 
the ingestion of lime powder. Magnesium is one of the micromolecular urinary inhibitors 
(Moe 2006). It has been shown to decrease the crystallization of CaOx by complexing 
with oxalate ions to fonn soluble magnesium oxalate, meaning that magnesium can 
reduce the amoWit of free oxalate ions in the urine (Desmars and Tawashi 1793; Hallson 
et al. 1982; Danielson 1985). However, this is contradicting because there was no 
significant decrease of oxalate excretion in this group after the ingestion of lime powder. 
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Crystallization experiments showed that lime inhibits nucleation (SEM, nucleation assay) 
in this group. Although it has been previously stated that promotion of nucleation is 
favourable, this mechanism is not as important as growth and aggregation. Therefore, the 
increase in nucleation is not crucial, but must nevertheless be considered as unfavourable. 
Lime showed an unfavourable promotion of crystal growth (growth assay) but a 
favourable inhibition of aggregation (aggregation assay). It also showed an unfavourable 
increase in free Ca2+ but a favourable decrease in BRI. These results indicate that lime 
powder had an inconclusive effect on reducing the urinary risk factors in black subjects. 
SEM observations revealed that COD crystals were precipitated in the baseline samples 
of white subjects, while black subjects deposited only COM crystals. The precipitation of 
COD crystals in white subjects is in agreement with the higher urinary calcium (albeit 
insignificant) excretion, which favours the formation of these crystals (Webber et al. 
2002). As mentioned in the previous paragraphs, lime powder affected other 
crystallization parameters differently in these two groups. Therefore, the present study 
has provided further evidence of different renal or gastrointestinal handling mechanisms 
in these two groups, in response to ingestion of lithogenic and antilithogenic challenges. 
Regarding its potential as a therapeutic agent, the effect of lime in black subjects is 
inconclusive. However, several favourable results were observed in white subjects which 
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6.1 DISCUSSION AND CONCLUDING REMARKS 
The effect of citrus fruit (lime) on CaOx crystallization in the urine of South Africa's 
population groups has not been previously investigated. Therefore the objective of this 
dissertation was to measure the relative inhibitory activity of lime, (in the fonn of a 
powder), in artificial and real urine and to investigate its effect in black and white 
subjects. 
As much as the artificial urine is different from the more complex real wine, the in vitro 
study of the real urine (Chapter 4) showed that the effect of lime solutions in the two 
media is similar. The CaOx MSL of both AU and real urine (Chapters 3 and 4) as well as 
that shown in the trial study (Chapter 5) showed that it is independent of the 
concentration of the lime solutions. The MSL of AU is different to that of real urine 
because the two media are different. AU is a simple inorganic solution while real urine is 
very complex with many micro/macro molecules present. The results of the present study 
show that lime does not affect the MSL in either of these solutions. This is not swprising 
because other inhibitory substances like citrate (Ryall et al. 1985), urinary 
glycosarninoglycans (GAGs) e.g. heparin sulphate (Suzuki and Ryall 1996), and proteins 
e.g. Tamm-Horsfall mucoprotein and phrothrombin fragment 1 (Grover et al. 1994; 
Grover and Ryall 2002) also do not have an effect on the CaOx MSL. 
Similar results in the AU and real urine studies (Chapters 3 and 4) were observed for 3 
crystallization mechanisms. These included promotion of nucleation and inhibition of 
both growth and aggregation after the addition of lime solutions in these two media. 
However, lime affected these parameters differently in the trial study (Chapter 5). In 
addition, lime treatment did not result in the same volume reduction as was the case when 
lime was added in vitro. Differences in urine composition might explain that. The reason 
might be the fact that there is a difference between dosing urine directly with lime 
solutions and ingestion thereof. The latter takes into account many metabolic processes 
that take place within the gastrointestinal tract following ingestion. 
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Previous researchers have reported that South African blacks have a decreased intake of 
calciwn and protein, both of which are regarded as risk factors for stone formation. In 
contrast to these reports, black subjects have in the present project showed a higher intake 
of total protein compared to whites due to a high intake of animal protein (Chapter 5). 
The same results were not observed in Chapter 4. It is further noted that a significantly 
low intake of calciwn in black subjects observed in Chapter 4 was not observed in the 
trial study (Chapter 5). Although it is surprising that these dietary intakes differed in these 
two studies as they were expected to give similar results, the reason might be due to the 
small nwnber of subjects who participated, thereby diminishing the statistical power of 
the studies. 
An interesting feature which occurred in the real urine studies (Chapters 4 and 5) 
regarding the differences between urine of black and white subjects was that the urine of 
white subjects showed predominantly COD crystal morphology while black subjects 
demonstrated COM morphology. This observation is not surprising since COD forms at 
higher calciwn concentrations and as mentioned before, white subjects have higher 
calciwn intake and therefore higher urinary calciwn excretion compared to blacks. In 
addition, the precipitation of COD crystals in this group is important because these 
crystals show a lower binding affinity for epithelial cell surfaces than COM crystals, thus 
inhibiting the crucial step in the formation of kidney stones (Wesson et al. 1998). 
The BRI values which were higher in whites than in blacks in both studies and the lower 
CaOx risk index (TRI) in blacks also showed yet another difference between these groups 
and these observations are consistent with blacks' lower stone incidence. 
Differences between the black and white responses in the present study support the 
general hypothesis which has been reported by researchers from the Kidney Stone 
Research Labomtory (University of Cape Town), (Lewandowski et al. 2001; Rodgers and 
Lewandowski 2002; Lewandowski et al. 2005), namely that the black and white 
population groups in South Africa have different renal handling when lithogenic and anti-
lithogenic (in the present study, anti-lithogenic) nutrients are administered. 
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Swprisingly, lime powder failed to significantly increase the urinary citrate excretion in 
both groups. Other non-parametric statistical tests also failed to reveal a significant 
increase. This was not expected because lime has a high content of citrate and the 
increase in urinary citrate excretion has been observed with other citrus studies (Honow et 
al. 2003; Kang et al. 2007; Penniston et al. 2007; Aras et al. 2008; Tosukhowong et al. 
2008). Contrarily, a citrus (lemon) study by Koff et al (2007) showed that lemon juice did 
not improve the urinary citrate. However, the failure of lime powder to increase urinary 
citrate in the present study may be due to natural difference in absorbing or handling 
citrate compared to those of previous studies, albeit that there is no evidence to support 
this notion. The other possible reason might be that the effect of lime requires more than 
7 days of regular ingestion to become apparent. 
Nevertheless, although lime powder failed to increase urinary citrate in either group, it 
however favourably decreased various urinary CaOx risk factors (urinary oxalate, TRI, 
free es?-+ and BRI) in the white group. This was not observed in the black group. 
The overall results of the various studies presented in this dissertation lead to the 
conclusion that lime powder may be regarded as a potential therapeutic agent for reducing 
the risk of CaOx kidney stones in the white group. The results also support the evidence 
that there is a difference between black and white subjects in their handling of lithogenic 
and antilithogenic dietary challenges. 
Rigorous controlled trials in healthy subjects and in kidney stone patients need to be 
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